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LC-PUFA during pregnancy reduces the risk of preterm birth 
before 34 weeks of gestation. Pregnant women should 
achieve an additional supply  ≥ 200 mg docosahexaenic acid 
(DHA)/day, usually achieving a total intake  ≥ 300 mg DHA/
day. Higher intakes (600–800 mg DHA/day) may provide 
greater protection against early preterm birth. Some studies 
indicate beneficial effects of pre- and postnatal DHA supply 
on child neurodevelopment and allergy risk. Breast-feeding 
is the best choice for infants. Breast-feeding women should 
get  ≥ 200 mg DHA/day to achieve a human milk DHA content 
of  ∼ 0.3% fatty acids. Infant formula for term infants should 
contain DHA and arachidonic acid (AA) to provide 100 mg 
DHA/day and 140 mg AA/day. A supply of 100 mg DHA/day 
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 Abstract 
 The Early Nutrition Academy supported a systematic review 
of human studies on the roles of pre- and postnatal long-
chain polyunsaturated fatty acids (LC-PUFA) published from 
2008 to 2013 and an expert workshop that reviewed the in-
formation and developed recommendations, considering 
particularly Asian populations. An increased supply of n–3 
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should continue during the second half of infancy. We do 
not provide quantitative advice on AA levels in follow-on 
formula fed after the introduction of complimentary feeding 
due to a lack of sufficient data and considerable variation in 
the AA amounts provided by complimentary foods. Reason-
able intakes for very-low-birth weight infants are 18–60 mg/
kg/day DHA and 18–45 mg/kg/day AA, while higher intakes 
(55–60 mg/kg/day DHA,  ∼ 1% fatty acids; 35–45 mg/kg/day 
AA,  ∼ 0.6–0.75%) appear preferable. Research on the re-
quirements and effects of LC-PUFA during pregnancy, lacta-
tion, and early childhood should continue. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Essential polyunsaturated fatty acids (PUFA) of the 
omega-3 (n–3) and omega-6 (n–6) series are of critical 
importance during early life, and they are known to play 
an essential role in growth and development. Intakes in 
pregnancy and early life are thought to affect the quality 
of growth and neurological and immune function in later 
life.
 The long-chain PUFA (LC-PUFA) eicosapentaenoic 
acid (EPA; n–3) and docosahexaenic acid (DHA; n–3), 
and arachidonic acid (AA, n–6), can be formed from the 
precursors α-linolenic acid (n–3) and linoleic acid (n–6), 
respectively. However, the rates of conversion of the pre-
cursor PUFA are low and are estimated to range from 
only 0.1 to 10%  [1–3] . Moreover, the conversion rates de-
pend on common polymorphisms in the fatty acid de-
saturase  (FADS) gene cluster  [4, 5] . Pregnant and breast-
feeding women with the less common genotypes have a 
very low ability to form EPA and DHA from ALA and AA 
from LA, respectively  [6–8] . Conversion rates of precur-
sor PUFA in infants, and particularly in premature in-
fants, have been reported as insufficient to allow for bio-
chemical and functional normality  [9, 10] .
 Information on the roles of LC-PUFA during preg-
nancy, lactation, and infancy was reviewed and intake 
recommendations were provided in 2007 and 2008  [11, 
12] . Since then, many new studies and meta-analyses 
have provided new information on the role of LC-PUFA 
in maternal and infant nutrition and on their impact on 
health and development. Therefore, the Early Nutrition 
Academy (ENA) decided to have the recent information 
systematically reviewed, and recommendations for prac-
tice were derived by experts in PUFA, perinatal nutrition, 
and health, taking into account particularly the dietary 
intake and conditions of Asian populations. The ENA is 
a nonprofit society created by and representing the part-
ners of international research projects funded by the Eu-
ropean Commission and the Australian National Health 
and Medical Research Council that perform research on 
food and dietetic products in pregnancy and early child-
hood, in part also in collaboration with commercial part-
ners (e.g. www.project-earlynutrition.eu and www.nutri-
menthe.eu). The ENA aims to promote knowledge of hu-
man nutrition in early life, to stimulate quality research 
in this and related areas of science, nutrition, and health, 
and to disseminate such knowledge.
 Methods 
 We performed a systematic search of the literature databases of 
PubMed using the following search strings: (unsaturated fatty ac-
ids OR omega 3 fatty acids OR fish oils OR long-chain omega-3 
fatty acids OR docosahexaenoic acids OR omega-6 fatty acids OR 
arachidonic acid) AND (pregnant women OR pregnancy OR lac-
tating women OR breastfeeding OR lactation OR infants OR in-
fancy).
 The search was limited to studies in humans, published during 
the last 5 years (September 2008 to September 2013), in the English 
language and reporting functional outcomes. All systematic re-
views, meta-analyses, and randomized controlled trials (RCT), 
were included. In addition, we also evaluated relevant observa-
tional studies. Studies that included interventions with essential 
fatty acids combined with micronutrients in lipid-based supple-
ments or in fat-based flour, meant to be added to homemade 
meals, were not included in this review despite the fact that a num-
ber of these studies reported benefits for children’s growth and 
development  [13, 14] . In addition, further relevant publications 
identified by the group of participating experts were considered. 
An expert workshop was hosted by the ENA in Singapore prior to 
the 8th World Congress on Developmental Origins of Health and 
Disease (DOHaD) in November 2013. Participants were invited 
based on their expertise in the areas of PUFA, perinatal nutrition, 
and health, while a focus was placed on experts from Asian coun-
tries. At the workshop, the evidence was reviewed and discussed in 
detail. All conclusions and recommendations presented in this 
manuscript were agreed upon by consensus.
 Results 
 A total of 20 systematic reviews and/or meta-analyses 
and 78 original reports of RCT that met the inclusion cri-
teria were found in the systematic literature review. These 
78 original reports related to 44 individual studies (13 in 
pregnant women, 6 in pregnant and lactating women, 2 
in lactating women, 3 in preterm infants, 14 in term in-
fants, and 6 in older infants) and are summarized in  tables 
1–5 .
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 Evidence from Pregnant and Lactating Women 
 We evaluated a total of 21 individual studies published 
since 2008 identified by the systematic search. These 
studies investigated the impact of n–3 LC-PUFA inter-
ventions on pregnancy and longer-term outcomes. Elev-
en of these studies supplemented with LC-PUFA during 
pregnancy, 6 studies supplemented both during pregnan-
cy and during lactation, 2 studies supplemented mothers 
during pregnancy and subsequently the infants after de-
livery, and 2 studies supplemented during lactation only. 
In addition, 12 systematic reviews or meta-analyses were 
found. Two of the studies in pregnant women published 
since 2008 were performed in women from low- or mid-
dle-income countries, i.e. Mexico  [15] and China  [16] .
 Pregnancy Outcomes 
 A systematic review of 15 RCT found that women re-
ceiving an additional n–3 LC-PUFA supply in different 
amounts during pregnancy delivered infants with a 
slightly higher birth weight (42.2 g; 95% CI 14.8–69.7), 
with a 26% lower risk of early preterm delivery (<34 
weeks) (RR 0.74; 95% CI 0.58–0.94). In addition, supple-
mented women showed a trend toward a decreased risk 
of preterm delivery (RR 0.91; 95% CI 0.83–1.02)  [17] . 
Three previous meta-analyses also evaluated such effects. 
Szajewska et al.  [18] reported a significant increase in the 
mean pregnancy duration of 1.6 days, along with a slight 
increase in infant size at birth with a nonsignificant trend 
toward fewer preterm births before 37 weeks of gestation 
(RR 0.67; 95% CI 0.41–1.10, n.s.). A Cochrane review by 
Makrides et al.  [19] included 6 randomized trials on ma-
rine oil supplementation in different amounts during 
pregnancy, involving 2,783 women. Women allocated to 
a marine oil supplement had a small but significant in-
crease in the length of gestation of 2.6 days, along with a 
slightly higher infant birth weight (47 g; 95% CI 1–93). 
The number if early preterm births before 34 completed 
weeks of gestation was significantly reduced by marine oil 
(RR 0.69, 95% CI 0.49–0.99; 3 trials, 2,440 women)  [19] . 
In high-risk pregnancies, n–3 LC-PUFA supplementa-
tion showed an even more marked and significant reduc-
tion in the number of early preterm births before 34 weeks 
of gestation (RR 0.39; 95% CI 0.18–0.84)  [20] .
 Three studies published after 2008 confirmed the 
positive effects of n–3 LC-PUFA interventions during 
pregnancy on birth-size, with larger birth weights and 
head circumferences in infants of supplemented moth-
ers  [15, 21, 22] . In one of these studies in Mexico, these 
effects were only seen in firstborn infants  [15] . In a small 
study of 48 pregnant women who had consumed cereal-
based food fortified with DHA, a lower ponderal index 
but no effect on birth weight or length were reported 
 [23] . Four studies have been published since 2008 re-
porting on gestational age at birth and the risk of early 
preterm delivery. Makrides et al.  [24] performed a dou-
ble-blind RCT in 2,399 women with singleton pregnan-
cies supplemented from mid-gestation to birth with 
DHA-rich fish oil capsules providing 800 mg DHA/day 
or matched vegetable oil capsules without DHA. The ad-
justed RR for early preterm birth before 34 weeks of ges-
tation was significantly reduced to 0.49 (95% CI 0.25–
0.94; p = 0.03), while the mean gestational age was pro-
longed by 1 day (p  = 0.05)  [24] . Carlson et al.  [22] 
performed a double-blind RCT supplementing women 
during the second half of pregnancy with 600 mg DHA 
daily or placebo. Supplementation led to a longer mean 
duration of gestation by 2.9 days (p = 0.041), along with 
a higher birth weight (plus 172 g; p = 0.004), length (plus 
0.7 cm; p = 0.022), and head circumference (plus 0.5 cm; 
p = 0.012). Early preterm births before 34 weeks of ges-
tation were markedly reduced from 4.8% in controls to 
0.6% in the intervention groups (p  = 0.025), and the 
length of hospital stay in infants born preterm was 
shorter (8.9 vs. 40.8 days; p = 0.026)  [22] . No safety is-
sues occurred. In contrast, 2 other studies that provided 
lesser amounts of n–3 LC-PUFA did not observe a ben-
eficial effect of supplementation on premature birth  [15, 
25] . These studies that did not observe a benefit of sup-
plementation were performed in Mexican women and 
in women with major depressive disorders. Only one 
study reported on pregnancy complications as an out-
come. In Mexico, no impact was found on gestational 
diabetes and preeclampsia after maternal supplementa-
tion with DHA in pregnancy  [26] .
 A cross-sectional study in rural, poor Southern Indian 
women found a significant positive correlation between 
EPA/DHA intake during pregnancy and birth weight 
 [27] . Women whose fish intake was in the lowest tertile 
in the third trimester of pregnancy had a significantly in-
creased adjusted odds ratio for the risk of low birth weight 
compared to those in the highest tertile, but there was no 
difference in gestational duration.
 In conclusion, the results of 4 meta-analyses and 2 re-
cent large RCT consistently showed a protective effect of 
n–3 LC-PUFA supplementation during pregnancy with 
respect to a reduction in the incidence of early preterm 
births (<34 weeks gestation). The impressive effect sizes 
of the reductions were 26% in the most recent meta-anal-
ysis and 51 and 87.5%, respectively, in 2 more recent large 
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RCT using higher n–3 LC-PUFA dosages (600 or 800 mg 
DHA/day). Two other studies found no significant ef-
fects. No dose-response studies with direct comparisons 
of the effects of different dosages on early preterm birth 
have been performed. However, the greater effect sizes 
observed in the recent studies using 600–800 mg DHA/
day compared to the earlier studies providing lower dos-
ages are suggestive of a possible greater protective effect 
at higher intake levels, whereas no adverse effects were 
reported with the higher dosages. n–3 LC-PUFA supple-
mentation in pregnancy also led to a small increase in 
infant size at birth, whereas there was no evidence of rel-
evant untoward effects. Given that early preterm birth be-
fore 34 weeks of gestation markedly increases infant 
short- and long-term morbidity as well as mortality, it is 
advisable that pregnant women aim to achieve a regular 
supply of preformed n–3 LC-PUFA from foods such as 
oily fish and seafood or from supplements. A regular sup-
ply prior to pregnancy may also be beneficial since it con-
tributes to the accumulation of body stores of n–3 LC-
PUFA that can be utilized and thus contribute to securing 
protective blood and tissue levels of n–3 LC-PUFA dur-
ing pregnancy (and during lactation; see below).
 Cognitive and Visual Development 
 In several observational cohort studies, beneficial ef-
fects of n–3 or fish intake during pregnancy and/or lacta-
tion on the developmental outcomes and cognition of the 
offspring up to 14 years of age have been reported, even 
after adjusting for potential confounding factors  [28–30] .
 However, the findings or outcomes from RCT are con-
flicting. A meta-analysis of 11 RCT involving 5,277 par-
ticipants found no significant differences in standardized 
psychometric test scores for cognitive, language, or mo-
tor development in the offspring of mothers who had 
been supplemented with LC-PUFA during pregnancy 
 [31] . There was a suggestion of higher cognitive develop-
ment scores at later ages (2–5 years) in children of supple-
mented mothers derived from 2 trials. No results on vi-
sual outcomes could be calculated because of the variety 
of visual assessments used in the different studies.
 Five studies have been published since 2008 evaluating 
cognitive outcomes and visual acuity after n–3 LC-PUFA 
supplementation during pregnancy; one of these studies 
extended the supplementation to the newborns until they 
reached 6 months of age  [32] . Three of these studies did 
not observe beneficial effects of supplementation on the 
overall cognitive test scores at 18 months  [24] or 6.5 years 
of age  [33] , or on visual development at 3–6 or 4 months 
of age  [34, 35] . A study in 67 pregnant women given a 
daily supplement of 600 mg DHA/day observed higher 
fetal heart rate variability measured at 24, 32, and 36 
weeks of gestation and higher scores on a newborn neo-
natal behavioral assessment scale  [36] . A study in 48 preg-
nant women in the USA who consumed cereal-based 
DHA-fortified food during pregnancy observed fewer 
sleep arousals in the infants of supplemented women, 
which the authors identified as an early marker of im-
proved neurodevelopment  [37] .
 Observational studies found a link between LC-PUFA 
status markers during pregnancy and at birth, reflecting 
a maternal supply before and during pregnancy, and later 
neurodevelopmental outcomes. Steer et al.  [8] explored 
the link between maternal red blood cell contents of LC-
PUFA in pregnancy and children’s IQ at about 8 years in 
2,839 mother-child pairs from the Avon Longitudinal 
Study of Parents and Children in the UK. Low maternal 
AA levels in pregnancy were linked to lower performance 
IQ, i.e. –2.0 points (95% CI –3.5 to –0.6; p = 0.007; in-
crease in R 2  = 0.27%), and low levels of DHA (22: 6n–3) 
with a reduction of full scale IQ of –1.5 points (95% CI 
–2.9 to –0.1; p = 0.031; R 2  = 0.15%). Kohlboeck et al.  [38] 
reported a longitudinal cohort study with analysis of ve-
nous cord blood glycerophospholipid fatty acids at birth 
and behavior at age 10 years in 416 children in Munich, 
Germany. A 1% increase in DHA in cord blood serum 
decreased total behavioral difficulties by (exp)β adj  = 0.93 
(SE 0.02; p = 0.0001) and hyperactivity or inattentiveness 
by (exp)β adj  = 0.94 (SE 0.03; p = 0.04). Higher LC-PUFA 
concentrations in cord blood serum were associated with 
fewer emotional symptoms [(exp)β adj  = 0.95, SE 0.03; p = 
0.01], and similarly higher AA concentrations were asso-
ciated with fewer emotional symptoms [(exp)β adj  = 0.94, 
SE 0.03; p = 0.03]. The results of these observational stud-
ies together suggest that the maternal AA and DHA status 
is relevant for fetal neural development and the long-term 
development of cognitive and emotional outcomes.
 Two studies evaluated the impact of n–3 LC-PUFA 
supplementation during pregnancy and extended during 
the first 3 months postpartum on children’s later cogni-
tive development at 18 months  [39] or at 7 years of age 
 [40] . No beneficial effects of supplementation were found 
on mental development index (MDI) scores at 18 months 
or on cognitive scores on the Kaufman Assessment Bat-
tery for Children (KABC) test at 7 years.
 LC-PUFA supplementation in breast-feeding women 
was reviewed in a Cochrane analysis  [41] . A pooled anal-
ysis of outcomes in 5 clustered areas of neurodevelop-
ment, i.e. language development, intelligence/problem-
solving ability, psychomotor development, motor devel-
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opment, and child attention, reported no significant 
overall effects in the rather heterogeneous studies, except 
for improved sustained attention at 5 years observed in a 
study supplementing breast-feeding women for 4 months 
with 200 mg DHA/day  [42] .
 Since 2008, two studies have been published evaluat-
ing the impact of supplementation during breast-feeding. 
Jensen et al.  [42] followed children of mothers who had 
been supplemented with 200 mg DHA/day during the 
first 4 months of lactation and at the children’s age of 
5 years observed higher scores on the sustained-attention 
subscale in the children of supplemented mothers. Previ-
ously reported findings from the same study  [43] demon-
strated a better performance of children of DHA-supple-
mented mothers on tests of psychomotor development at 
30 months of age, which might be explained by improved 
sustained attention as documented at the older age. An-
other trial in breast-feeding Danish women  [44] evalu-
ated the impact of supplementation during the first 
4 months of lactation on cognitive test scores at 7 years of 
age. That study found a faster speed of information pro-
cessing in children of previously supplemented mothers, 
and lower scores for inhibitory control/working memory 
in children with a higher DHA status at 4 months.
 Further evidence has emerged from analysis of the in-
teraction of breast-feeding and genotype effects.  Steer et 
al.  [45] explored the interaction of postnatal breast-feed-
ing and variation in the genotypes for  FADS enzymes 
with regard to IQ scores assessed at about 8 years of age 
in 5,934 children born in the early 1990s in the UK. 
Breast-feeding was associated with higher IQ scores than 
bottle-feeding, which was not LC-PUFA supplemented 
or enriched at the time of the study. In children with a 
 FADS genotype linked to a low endogenous LC-PUFA 
synthesis, breast-feeding supplying LC-PUFA provided 
an added benefit of more than 4 IQ points at school age 
compared to infants with a genotype supporting a more 
active LC-PUFA formation. Similarly, Morales et al.  [46] 
found that Spanish children who had been previously 
bottle-fed formula without added LC-PUFA had an 8- to 
9-point disadvantage in cognitive scores assessed at 14 
months or at 4 years if there were homozygous for  FADS 
genotypes linked to a low endogenous LC-PUFA synthe-
sis compared to a genotype leading to more active LC-
PUFA formation. Assuming that  FADS genotypes are 
distributed at random in the population and are not re-
lated to the decision to breast-feed (the concept of ‘men-
delian randomization’), these data support a causal rela-
tionship between LC-PUFA supply during lactation and 
status in infancy and later cognitive achievements.
 We conclude that the totality of recent RCT which are 
heterogeneous in outcomes and methods of assessment 
does not provide conclusive evidence of the benefits of 
added LC-PUFA supplementation during pregnancy 
and/or lactation for early cognitive or visual outcomes in 
offspring. However, the results of some high-quality ran-
domized trials and observational as well as gene-nutrient 
interaction studies point to biologically important benefi-
cial effects of an enhanced maternal pre- and postnatal 
LC-PUFA status on later attention, information process-
ing, and cognitive performance.
 The LC-PUFA content of human breast milk is not 
only derived from the current dietary intake  [47] , but a 
large proportion also comes from maternal body stores of 
LC-PUFA that have been previously deposited  [48] . 
Therefore, it appears desirable to aim at securing an ad-
equate maternal pre- and postnatal LC-PUFA status also 
to ensure an adequate LC-PUFA supply to the breast-fed 
infant to support child development.
 Immune Response and Allergies 
 A systematic review that included 5 RCT on the effect 
of perinatal n–3 fatty acid supplementation on inflamma-
tory markers and allergic diseases concluded that n–3 
PUFA supplementation during pregnancy reduced the 
12-month prevalence of positive egg skin prick tests and 
childhood asthma  [49] . Since 2008, six studies have been 
published evaluating markers of immune response and/
or allergic diseases in children of mothers supplemented 
with n–3 LC-PUFA or oily fish during pregnancy. All of 
these studies reported some positive findings on selected 
immune markers and/or the incidence of (allergic) dis-
eases in the children of supplemented mothers. Supple-
mentation with LC-PUFA or consumption of 2 portions 
of oily fish/week during pregnancy resulted in improve-
ments in neonatal  [50–53] and maternal  [53, 54] immune 
responses, with attenuation of allergic inflammation, per-
haps influenced by the infant allergic status.
 Infants of supplemented mothers also showed lower 
rates of atopic eczema at 1 year of age  [55, 56] and allergic 
asthma at 19 years of age  [57] . A decreased occurrence of 
common colds and a shorter duration of common respi-
ratory illnesses in the first 6 months of life were observed 
in infants of Mexican mothers supplemented with 400 mg 
algal DHA/day during pregnancy  [58] . Four studies sup-
plemented mothers during pregnancy and extended the 
supplementation during the first 3 or 4 months postpar-
tum and reported positive effects on immune responses 
or allergic diseases. Furuhjelm et al.  [59] reported a lower 
prevalence of food allergy and a cumulative incidence of 
 Perinatal LC-PUFA Supply: Systematic 
Review and Recommendations 
Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
67
immunoglobulin E (IgE)-associated diseases in the first 
2 years of life after supplementing 145 at-risk pregnant 
women in Sweden with a provision of DHA and EPA dur-
ing pregnancy and the first 3.5 months of breast-feeding 
 [59] . Granot et al.  [60] found changes in CD4 and CD8 
cells compatible with attenuation of the proinflammatory 
response in the infants of 60 pregnant women supple-
mented with 400 mg DHA/day from early gestation until 
4 months postpartum. A lower prevalence of atopic der-
matitis (AD) was also observed in Finnish infants whose 
mothers had been supplemented with black currant seed 
oil during pregnancy until the cessation of breast-feeding, 
suggesting a possible beneficial role also for n–6 PUFA 
 [61] . Follow-up of adolescents whose mothers had been 
randomized to supplementation with fish oil or olive oil 
capsules during pregnancy showed that fish oil provision 
in pregnancy markedly reduced the risk of asthma and 
particularly of allergic asthma at the age of 16 years  [57] . 
 Observational studies also reported a protective effect 
of fish intake in pregnancy and infancy on the allergic 
disease risk. Sausenthaler et al.  [62] assessed 2,641 chil-
dren and their mothers in a prospective birth cohort 
study in Germany (LISA). Higher maternal fish con-
sumption (which provides n–3 LC-PUFA) during the last 
4 weeks of pregnancy significantly reduced the risk of 
child eczema up to the age of 2 years (adjusted OR 0.75; 
95% CI 0.57–0.98). Similarly, a higher fish consumption 
by pregnant women was linked to a lower allergic sensi-
tization of their children in Italy  [63] , less doctor-diag-
nosed eczema in children in The Netherlands  [64] , and 
less eczema, allergic sensitization, and atopic wheezing in 
Mexican children  [65] .
 Recently, Standl et al.  [66] reported a marked breast-
feeding-gene interaction effect on doctor-diagnosed 
asthma up to the age of 10 years. In children with an  FADS 
genotype resulting in low LC-PUFA synthesis, longer 
breast-feeding, which would support an improved LC-
PUFA status in infancy, reduced the asthma risk by 57–
61%, whereas there was no significant effect of breast-
feeding in children homozygous for the major genetic al-
lele  [66] . These studies lend further support to the 
conclusion that the LC-PUFA status in early life is very 
important for long-term protection against childhood al-
lergies.
 With respect to the infants’ anti-infectious response, 
increased IgG titers to common childhood vaccines were 
found in infants after LC-PUFA supplementation during 
pregnancy  [59] . Moreover, daily supplementation of 400 
mg DHA from algal oil compared to placebo from 18–22 
weeks of gestation to birth in a double-blind RCT in 
 Mexican pregnant women showed in infants (n = 834) 
beneficial effects of maternal DHA supplementation on a 
reduced rate of respiratory tract infections at the age of 
1 month (RR 0.76; 95% CI 0.58–1.00) and on the infant 
disease burden at the ages of 1, 3, and 6 months  [58] . For 
example, at the age of 6 months, the duration of fever was 
reduced by 20%, nasal secretions by 13%, dyspnea by 
54%, skin rashes by 23%, and other symptoms by 25%. 
These effects might be mediated by modulation of DNA 
methylation and Th1/Th2 balance  [67] .
 In summary, current evidence suggests a beneficial ef-
fect of oily fish intake or supplementation with fish oils or 
with DHA-rich algal oil during pregnancy on immune 
responses involved in allergic inflammation, on the inci-
dence of allergic conditions, and on anti-infectious pro-
tection and the infection disease risk in children.
 Maternal Depression 
 One systematic review included 10 articles (cohort 
studies, RCT, and pilot trials) that evaluated the impact 
of maternal n–3 fatty acid supplementation on perinatal 
maternal depression. Inconsistent results were observed, 
with 6 studies finding no association, 2 showing mixed 
results, and 2 reporting a positive association between 
n–3 PUFA and a reduced incidence of maternal perinatal 
depression  [68] . The authors concluded that the hetero-
geneity of the results could be explained by the heteroge-
neity of the studies, with different study durations and 
time periods and other differences in PUFA interven-
tions.
 Four studies evaluated maternal depression outcomes 
after supplementation with n–3 LC-PUFA during preg-
nancy and lactation. Three of those studies  [24, 69, 70] did 
not observe differences in maternal depressive symptoms 
after supplementation. A small study in 36 pregnant 
women in China with diagnosed major depressive disor-
ders found significantly lower depression scores after an 
8-week daily supplementation during pregnancy with 
3.4 g n–3 PUFA  [16] .
 In summary, evidence for the role of maternal n–3 LC-
PUFA supplementation in perinatal depression is incon-
clusive. More research is needed to confirm or refute the 
observation that mothers with more severe risks of de-
pression may benefit from supplementation.
 Growth, Obesity, and Early Markers of 
Cardiovascular Disease and Oxidative Stress 
 Maternal supplementation with 400 mg/day DHA 
from algal oil during pregnancy in Mexico increased in-
fants’ length at 18 months of age, but only in firstborn 
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children  [34] . No impact of cod liver oil supplementa-
tion during pregnancy and the first 3 months after de-
livery was found on children’s height, weight, or BMI at 
7 years of age  [40] . Maternal AA and n–6 LC-PUFA con-
centrations during gestation and lactation were nega-
tively related to the BMI and the ponderal index at 1 year 
of age  [21] , but no differences in abdominal fat mass or 
fat distribution were observed in infants of German 
mothers supplemented with 1,200 mg n–3 LC-PUFA 
from the 15th week gestation until 4 months postpartum 
 [71] .
 Three systematic reviews evaluated the impact of 
maternal n–3 fatty acid supplementation on children’s 
later body composition or body weight. The reviews in-
cluded studies that supplemented mothers during preg-
nancy, lactation, or both. Inverse associations between 
maternal n–3 LC-PUFA intake or supplementation and 
the children’s later body composition (adiposity, BMI, 
or body weight) were observed in some but not all stud-
ies  [72–74] . A recent review including 6 controlled trials 
of pre- or postnatal n–3 LC-PUFA supplementation 
concluded that currently there is little evidence to sup-
port the hypothesis that LC-PUFA supplementation 
during pregnancy and lactation prevents childhood 
obesity  [75] .
 Two controlled studies evaluated markers of early car-
diovascular disease (CVD) at 7 and 19 years of age, re-
spectively, in children whose mothers had been supple-
mented with fish oil or placebo during pregnancy  [76–
79] . No differences in adiposity, plasma lipids, plasma 
lipoproteins, blood pressure, heart rate, or heart rate vari-
ability were reported in Danish children aged 19 years 
whose mothers had been randomized to receiving daily 
fish oil, olive oil, or no oil during pregnancy. Adverse ef-
fects on blood pressure, energy intake, and physical activ-
ity at 7 years of age were observed in boys, but not in girls, 
after fish oil supplementation during the first 4 months of 
lactation  [76] . In contrast, lower umbilical cord blood in-
sulin concentrations were observed in infants of mothers 
who had been supplemented with cereal-based DHA-for-
tified food during pregnancy, but that study was small 
and suffered from methodological flaws  [23] .
 Two studies evaluated markers of oxidative stress and 
did not report any differences between pregnant mothers 
supplemented with LC-PUFA or oily fish and nonsupple-
mented mothers  [80, 81] .
 In summary, the current evidence for a possible pro-
gramming effect of maternal n–3 fatty acid supplementa-
tion on child growth, obesity risk, and early markers of 
CVD is limited and does not allow firm conclusions.
 LC-PUFA Supply to Infants Born at Full Term 
 A total of 14 original studies that evaluated the impact 
of n–3 LC-PUFA supplementation during infancy in 
term infants were included. In addition, we evaluated 6 
systematic reviews and meta-analyses that reported find-
ings in term infants.
 Cognitive Development 
 All meta-analyses in this area are limited by a large de-
gree of heterogeneity between the included studies, in par-
ticular regarding interventions, dosages, selected out-
comes, and methods of outcome assessment. Moreover, 
the available intervention trials did not adjust for genetic 
variation in PUFA metabolism ( FADS genotypes). A me-
ta-analysis of 15 randomized studies on the effects of LC-
PUFA supplementation in term infants did not show sig-
nificant beneficial effects of supplementation on either 
mental or psychomotor development  [82] . This finding 
was repeated in another meta-analysis including 12 trials 
involving 1,802 infants and demonstrating no significant 
effect of LC-PUFA supplementation of formula on early 
infant visual development and cognition  [83, 84] . Out-
comes regarding visual acuity were inconsistent: no over-
all benefits were reported in a Cochrane review, with 5 out 
of 9 studies not showing a beneficial effect  [82] . In con-
trast, a meta-analysis involving 1,949 infants from 19 
studies found a significant benefit for infants’ visual acuity 
after LC-PUFA supplementation up to 12 months of age 
 [83] . Studies that provided higher doses of DHA (at least 
0.32% in formula) and AA (at least 0.65% in formula) for 
a longer duration (>1 year) and measured visual acuity 
with electrophysiological tests were more likely to show 
beneficial effects of supplementation in term infants  [82] .
 Nine studies have been published since 2008 evaluat-
ing the impact of LC-PUFA supplementation in term in-
fants on several aspects of cognitive development. Two of 
these studies  [85, 86] have already been included in the 3 
meta-analyses  [82–84] .
 Studies have evaluated mental development, visual 
acuity, or motor development during infancy or in young 
childhood and the results have been mixed: one study 
providing high-dose fish oil with n–3 LC-PUFA but with-
out AA did not observe beneficial effects on Bayley Scale 
of Infant Development (BSID) scores  [87] , one observed 
a beneficial effect on the mental development index  [85] , 
and another study reported beneficial effects on visual 
acuity  [86] when 3 different DHA dosage groups were 
combined. These data may indicate that effects at young-
er ages may be too subtle to detect with smaller sample 
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sizes. Supplementation with LC-PUFA in term infants 
shortened the time to achieving a milestone of motor de-
velopment (sitting without support)  [88] .
 Four studies assessed cognitive development at school 
age when the children were 6 or 9 years of age. Two of 
these studies  [89, 90] reported beneficial effects on vari-
ous aspects of cognition (attention, fine-grained tasks, 
speed of processing, and problem solving), suggesting 
that the effects of LC-PUFA supplementation in early life 
may be better detectable at a later age in more specific or 
fine-grained tasks. The other 2 studies, however, reported 
no beneficial effects on selected outcomes in LC-PUFA-
supplemented children  [91, 92] .
 In summary, among the recently published studies, 
some studies supplementing formula for term infants 
with LC-PUFA found benefits with regard to visual, mo-
tor, and cognitive outcomes in early childhood, and even 
more pronounced benefits in later childhood. However, 
other studies found no significant beneficial effects. There 
was no evidence of untoward effects. There is a trend to-
ward a greater likelihood of benefit with higher dosages 
(DHA  ≥ 0.32% and AA  ≥ 0.66%) and a longer duration of 
a higher postnatal LC-PUFA supplementation (up to 
1 year of age). As discussed before, further evidence for 
the benefits of a postnatal LC-PUFA supply is derived 
from gene-nutrition interaction studies that report great-
er benefits of breast-feeding, which provides preformed 
LC-PUFA, in infants genetically determined to have a 
lower endogenous LC-PUFA synthesis  [45, 46] .
 Growth/Anthropometry 
 A systematic review of 13 studies in term infants found 
no effects of LC-PUFA supplementation on growth  [82] . 
Rosenfeld et al.  [93] performed a meta-analysis based on 
individual patient data of 901 children from 4 RCT of for-
mula milk with and without LC-PUFA and found no evi-
dence that supplementation affects children’s growth at 
18 months of age. A previous meta-analysis including 14 
trials with 1,846 infants showed no significant effect of 
LC-PUFA supplementation with infant formula on infant 
weight, length, or head circumference at any assessment 
age  [94] . Of interest, that meta-analysis reported that sup-
plementation of infant formulae with n–3 LC-PUFA but 
no AA showed a mean reduction in plasma AA of 25% 
relative to the control groups  [94] . The potential biologi-
cal relevance of these reduced AA levels is uncertain.
 Since 2008, five studies with LC-PUFA supplementa-
tion in term infants have reported effects on growth and/
or the evolution of the BMI during infancy  [95–98] or at 
9 years of age  [99] . None of these studies observed differ-
ences in anthropometric measurements between supple-
mented and nonsupplemented infants, and there was no 
effect of fish-oil supplementation on growth hormone 
IGF-1 production in a study in Denmark  [98] .
 In summary, the available studies published to date do 
not provide evidence that LC-PUFA supplied to term in-
fants would change infant or later childhood growth or 
obesity risk.
 Allergies and the Immune Response 
 Studies evaluating the effect of LC-PUFA as well as 
other nutrient interventions on AD in children were re-
cently reviewed  [100] . The authors concluded that 
γ-linolenic acid supplementation in healthy infants seems 
to reduce the severity of AD. Supplementation with pre-
biotics and black currant seed oil (γ-linolenic acid and 
n–3 fatty acids) was effective in reducing the development 
of AD.
 We found 4 studies published since 2008 that evalu-
ated the impact of LC-PUFA supplementation in term 
infants on immune markers and/or allergies. Three of 
these studies found beneficial effects of supplementation 
on immune markers  [101, 102] or allergic diseases  [103] . 
D’Vaz et al.  [102] randomized 420 term infants with a 
high risk of allergy to a daily supplement of fish oil (280 
mg DHA, 100 mg EPA) or placebo from birth until 
6 months of age. They found lower allergen-specific Th2 
responses and elevated Th1 responses in the fish oil 
group, suggesting a potentially allergy-protective effect 
on immune function  [102] . Improved immune parame-
ter responses after LC-PUFA supplementation were also 
observed in formula-fed term infants at 16 weeks of age 
 [101] . In contrast, no differences in responses to child-
hood vaccines were observed after n–3 LC-PUFA and AA 
supplementation in 12-month-old formula-fed term in-
fants in Australia  [97] .
 Term infants receiving different dosages of DHA 
(0.32–0.36% fatty acids) and AA (0.64–0.72%) from 1–9 
days of life until 12 months of age had lower odds of de-
veloping lower respiratory tract infections, wheezing/
asthma, or other allergic diseases than controls, regard-
less of the dosage of DHA received  [103] . No differences 
in childhood allergic diseases were observed in infants 
with a high atopy risk at 6 months of age, despite the fact 
that immune parameters had been altered  [104] , suggest-
ing that longer follow-up times may be required before 
effects on disease become apparent.
 Protective effects of fish intake with complementary 
feeding in infancy on allergic conditions were found in 2 
large prospective birth cohort studies in Scandinavia. In 
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a study in 4,921 infants, introduction of fish prior to the 
infant age of 9 months reduced the eczema risk at 1 year 
(RR 0.76; 95% CI 0.62–0.94; p = 0.009)  [105] . In 4,089 
children followed from birth, provision of more than 2–3 
portions of fish per month in infancy compared to less the 
2 portions per month at the age of 4 years led to a signifi-
cantly reduced risk of asthma (RR 0.68; 95% CI 0.51–
0.92), eczema (RR 0.69; 95% CI 0.57–0.84), allergic rhini-
tis (RR 0.57; 95% CI 0.45–0.73), any allergic disease (RR 
0.65; 95% CI 0.54–0.77), and allergic sensitization (RR 
0.66; 95% CI 0.53–0.82)  [106] . 
 Further support for the conclusion that the LC-PUFA 
status in infancy impacts the allergic disease risk stems 
from the observation of marked protective effects of 
breast-feeding for at least 3 months, which reduces the 
risk of physician-diagnosed asthma at up to 10 years of 
age in subgroups defined by LC-PUFA metabolism. 
Breast-feeding with the provision of LC-PUFA reduced 
the asthma risk up to 10 years of age by about one half in 
children who had an  FADS genotype determining a low 
LC-PUFA synthesis.
 In summary, fish intake and an enhanced LC-PUFA 
status in infancy appear to have a protective effect on the 
development of allergic diseases in childhood.
 Other Outcomes 
 de Jong et al.  [91] measured the CVD risk at 9 years of 
age in term infants who had been supplemented with LC-
PUFA formula (n = 146; 0.45% AA and 0.30% DHA) or 
standard formula (n = 169) during the first 2 months of 
life. No differences in blood pressure or heart rate were 
observed between the 2 intervention groups.
 In a study in Thailand, 144 healthy term infants were 
supplemented with whey-based formula containing LC-
PUFA and oligosaccharides or placebo formula from 30 
days to 4 months of life  [95] . Beneficial effects on gas-
trointestinal comfort (gastric transit time, intestinal 
transit time, hard stools, and stool microbiota) were re-
ported.
 Colombo et al. [107] randomized 133 infants born at 
term to receive for the first year of life formula either with 
no LC-PUFA or with DHA at levels of 0.32, 0.64, or 
0.96% fatty acids combined with 0.64% AA. All LC- 
PUFA-enriched formula groups showed a reduced heart 
rate, without a recognizable dose-response relationship 
to levels of DHA intake  [107] . These results confirm pre-
vious observations by Pivik et al.  [108] who reported 
higher heart rates and lower values for heart rate vari-
ability measures in infants fed diets without DHA com-
pared to DHA-containing formula. The effects appeared 
from 4 months onwards and were interpreted as in-
creased parasympathetic tone in infants receiving DHA. 
In adults, a decreased heart rate is considered a positive 
health outcome.
 Older Infants 
 Five studies published since 2008 have assessed the ef-
fect of LC-PUFA supplementation in older infants (aged 
>3 months) and young children. One of these studies was 
performed in a disadvantaged population of infants from 
a low-income country  [109] . Overall, very few positive ef-
fects of LC-PUFA supplementation in older infants and 
young children have been reported since 2008. In  Gambia, 
LC-PUFA supplementation in healthy infants from 3 to 
9 months of age increased the mid-upper-arm circumfer-
ence and skinfold thickness at 12 months of age  [109] , 
whereas no growth effect was observed in Danish infants 
supplemented with fish oil from 9 to 18 months of age 
 [110] . No effects on morbidity or gut integrity were found 
in the Gambia study  [109] . Fish oil supplementation 
modified the fecal microflora in a subgroup of infants 
from the Danish study who had been weaned prior to the 
onset of supplementation  [111] .
 A study in Australian children randomized to active 
diet interventions to increase n–3 and decrease n–6 in-
takes from weaning until 5 years of age or controls and 
did not find changes in blood pressure or arterial struc-
ture at 8 years of age  [112] .
 Observations in infants who had been supplemented 
with fish oil from 9 to 12 months of age showed a 6% lon-
ger mean RR interval in fish-oil-supplemented boys (p = 
0.007). Irrespectively of gender, there was an association 
between RR interval changes and erythrocyte n–3 PUFA 
(p < 0.001), suggesting a beneficial effect of fish oil supple-
mentation in older infants on early markers of CVD risk 
 [113] . Fish oil supplementation also induced beneficial 
effects on free-play scores and looking behavior and de-
creased the systolic blood pressure  [114] .
 Evidence in Preterm Infants 
 We evaluated data from 3 trials in preterm infants that 
published results since 2008. Most studies in preterm in-
fants evaluated the effects of DHA supplies with human 
milk or formula near a 0.2–0.3% fat content. This amount 
is considered insufficient to support the average daily 
whole-body DHA accretion in excess of 50 mg/kg of body 
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weight that occurs in utero, which requires a DHA supply 
of about 1% human milk or formula fat  [115] . In a large 
RCT, Makrides et al.  [115] randomized 657 preterm in-
fants to a conventional (0.3%) or higher (1%) DHA sup-
ply, along with about 0.6% AA, from day 2 to day 4 of life 
until a term-corrected age. The findings of that trial were 
reported in a number of different publications  [116–119] . 
In addition, one meta-analysis specifically reported on 
the effects of LC-PUFA supplementation in preterm in-
fants  [120] .
 Cognitive Development 
 Four out of 7 studies included in the meta-analysis 
 [120] did not show a beneficial effect of supplementation 
on cognitive outcomes evaluated at 12 or 18 months of 
age. The 3 trials that showed beneficial effects on cogni-
tive development all used the newer version of the BSID, 
suggesting that other methods might not have been sensi-
tive or precise enough to detect effects. No beneficial ef-
fects of LC-PUFA supplementation on visual acuity were 
seen in the 16 studies included in the meta-analysis that 
evaluated visual acuity  [120] .
 Two of the 3 studies that reported outcomes on child 
neurodevelopment showed no beneficial effects of LC-
PUFA supplementation in preterm infants on cognitive 
outcomes at an early age [18 months; school age (lan-
guage)] or behavior at 3 or 5 years of age (general cogni-
tive tests at 10 years of age)  [115, 121, 122] . However, 
beneficial effects of supplementation were observed in 
certain subgroups. For instance, girls provided a high 
DHA intake (1%) along with AA had higher MDI scores 
at 18 months of age  [115] . In the total population, the oc-
currence of significant mental delay (mental develop-
mental index <70) at 18 months was markedly reduced by 
one half (p = 0.03), which is considered a major benefit 
for the developmental outcome.
 Another study in children aged 10 years found higher 
language scores in children who previously as preterm 
infants had been randomized to a DHA-containing for-
mula compared to controls who did not get DHA in ear-
ly life  [122] . In addition, children who received DHA for-
mula and no breast milk had better IQ and memory scores 
at 10 years of age, whereas this effect was not apparent in 
those who received formula with breast milk (which pro-
vides DHA)  [122] . Beneficial effects of supplementation 
on recognition and problem solving at 6 months of age 
were also observed in a group of very preterm infants 
(birth weight <1,500 g) who had been supplemented with 
DHA and AA in the first 9 weeks of life  [123] . Better vi-
sual acuity at 4 months’ corrected age was observed after 
DHA-supplemented formula in Australian preterm in-
fants  [124] .
 In summary, while there is considerable heterogeneity 
among the available studies, there are consistent indica-
tions that an LC-PUFA supply to preterm infants can 
have benefits for visual and cognitive outcomes, with ev-
idence from one large high-quality trial indicating DHA 
dose dependency. Certain subgroups of preterm infants, 
e.g. with a lower birth weight, may achieve a greater ben-
efit from a preformed LC-PUFA supply.
 Growth/Anthropometry 
 Preterm infants fed with high-DHA formula during 
early infancy in the Australia DINO trial were 0.7 cm lon-
ger at 18 months of age, and those born with a higher 
birth weight ( ≥ 1,250 g) also had an increased later weight 
 [118] . Higher body weights at 10 years of age in girls, but 
not in boys, were also observed in children who had been 
born preterm and had received LC-PUFA-supplemented 
formula until 9 months of age  [122] . However, these re-
sults were not confirmed by a meta-analysis, which did 
not find effects of providing LC-PUFA to preterm infants 
on weight, length, or head circumference at 12 months (4 
studies) or 18 months (2 studies) in spite of an increased 
weight and length at 2 months postterm in supplemented 
infants  [120] .
 In summary, there are conflicting data on the effects of 
LC-PUFA supply to preterm infants on postnatal growth, 
with some data indicating potential benefits for length 
growth in early childhood.
 Other Outcomes in Preterm Infants 
 A reduced incidence of reported hay fever at 12 and 18 
months of age and a reduction in chronic lung disease in 
boys and in infants born with a birth weight <1,250 g were 
observed in preterm infants randomized to a higher DHA 
supply (1%) along with AA as compared to a lower DHA 
supply (0.3%) in the previously cited study by Makrides 
and coworkers  [117] . An earlier study in preterm infants 
demonstrated comparable lymphocyte populations, cy-
tokine production, and antigen maturity between infants 
receiving LC-PUFA-supplemented formula and those re-
ceiving human milk, whereas infants receiving an unsup-
plemented formula differed in these immune parameters 
 [101, 125] .
 Follow-up of a subgroup of previously preterm born 
children at the age of 10 years did not show differences in 
growth or blood pressure, whereas a subgroup analysis 
among girls who had received formula with added DHA 
but no AA postnatally had a slightly higher blood pres-
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sure, but there were no significant differences after ad-
justment for current body weight  [126] .
 In summary, the reported positive effects of early LC-
PUFA supplementation in preterm infants on chronic 
lung disease and the immune response are promising and 
should prompt further investigation.
 Recent Recommendations on Pre- and Postnatal 
LC-PUFA Supply 
 Previously, scientific experts and learned societies rec-
ommended that pregnant and lactating women should 
achieve an average daily intake of at least 200 mg DHA, 
which can be reached by eating 2 portions of fish per week 
if this includes oily fish  [11, 12, 127, 128] . Alternatively, 
the use of supplements has been recommended for wom-
en that do not achieve this level of fish consumption. 
There is a broad consensus that breast-feeding, which 
provides preformed LC-PUFA, is the optimal choice for 
infant feeding  [129].  It was also concluded that formulae 
for term infants should contain DHA at levels between 0.2 
and 0.5 weight percent of total fat, with the minimum 
amount of AA at least equivalent to the content of DHA. 
The dietary LC-PUFA supply should continue after the 
first 6 months of life, but no quantitative recommenda-
tions were provided since there was not sufficient infor-
mation at that time.
 The European Food Safety Authority (EFSA) deter-
mined adequate intakes per day of 250 mg for EPA plus 
DHA for adults based on cardiovascular considerations 
and an added 100–200 mg preformed DHA during preg-
nancy and lactation to compensate for oxidative losses 
of maternal dietary DHA and accumulation of DHA in 
the body fat of the fetus/infant  [130] . In the year 2010, 
the EFSA further recommended a DHA intake of ap-
proximately 20–50 mg/day for young infants aged 0–6 
months and an intake of 100 mg DHA at 6–24 months 
to support optimal growth and development. More re-
cently, in 2013, the EFSA considered the following nu-
trient intakes adequate for the majority of infants and 
young children: 100 mg DHA/day and 140 mg AA/day 
from birth to age <6 months, 100 mg DHA/day from 6 
to <24 months, and 250 mg EPA + DHA/day after the 
age of 24 months  [131] . Recently, the EFSA shared a 
draft opinion on the compositional requirements of in-
fant and follow-on formulae and advised that both in-
fant and follow-on formulae should contain 20–50 mg 
DHA/100 kcal (at an assumed mean fat content of 5.2 
g/100 kcal,  ∼ 0.38–0.96% of fat), while it was not consid-
ered necessary to set a minimum requirement for AA 
content  [132] . However, this panel notes that no ade-
quate clinical studies have evaluated the suitability and 
safety of feeding infant formula from birth with DHA 
contents of up to about 1% fat and no content of AA. 
Therefore, the EFSA proposal is not supported by this 
panel.
 In 2010, the Food and Agriculture Organization of 
the United Nations (FAO) concluded that for pregnant 
and lactating females the minimum intake for optimal 
adult health and fetal and infant development is 0.3 
g/ day EPA + DHA, of which at least 0.2 g/day should be 
DHA  [133] . For infants aged 0–6 months, the FAO rec-
ommended a DHA intake of 0.1–0.18% of energy intake 
and an AA intake of 0.2–0.3% of energy intake based on 
human-milk composition. For infants above the age of 
6 months, a DHA supply of 10–12 mg/kg/day was rec-
ommended without specifying a requirement for AA 
 [133] .
 Recent recommendations for the compositional re-
quirements of follow-up formula suitable for feeding 
from the age of about 6 months onwards stipulate an 
optional DHA content of up to 1% fatty acids, while the 
evidence available was considered insufficient to set a 
minimal quantitative requirement for added AA in fol-
low-up formula that provides DHA  [134] . This was 
based on the consideration that the ability to maintain 
AA stores from endogenous synthesis increases during 
the second half of the first year of life  [135] , and that di-
etary preformed AA is usually provided by a variety of 
complementary foods during the second half of the first 
year of life.
 For preterm infants, daily intakes of 12–30 mg DHA 
and 18–42 mg AA per kilogram of bodyweight or 11–27 
mg DHA/100 kcal of energy intake and 16–39 mg AA/100 
kcal were recommended by the European Society for Pae-
diatric Gastroenterology, Hepatology and Nutrition 
( ESPGHAN) in 2009  [136] , though these recommenda-
tions were developed before the full information on the 
trial in preterm infants evaluating the suitability and safe-
ty of higher dosages  [117, 118, 137] had become available. 
It was also recommended that the ratio of AA to DHA 
should be in the range of 1.0–2.0 to 1 (wt/wt), and the EPA 
(20: 5n–3) supply should not exceed 30% of the DHA sup-
ply  [136] . A recent international expert group with con-
tributors from all 5 continents reviewed the nutritional 
needs of very-low-birth weight infants (birth weight 
<1,500 g). They concluded that very-low-birth weight in-
fants should receive per kilogram and per day between 
385 and 1,540 mg linoleic acid and >55 mg α-linolenic 
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acid. Intakes of DHA ranging from 18 to 60 mg and in-
takes of AA ranging from 18 to 45 mg were considered 
reasonable, while EPA intakes should not exceed 20 mg; 
however, DHA intakes of 55–60 mg, along with AA in-
takes of 35–45 mg, were considered preferable (all per kg 
and per day)  [138] .
 LC-PUFA Supply in Asian Populations 
 Many populations in Asia have traditionally regularly 
consumed fish and seafood, and hence they have had a 
relatively high intake of preformed EPA and DHA. How-
ever, in recent years the fish intake has tended to mark-
edly decrease while the meat consumption has increased, 
with a resulting decreased intake of DHA and EPA and 
an increase in AA intake ( fig.  1 ), particularly among 
younger women ( fig. 2 ), as documented in the Japanese 
National Health and Nutrition Survey  [139] and in the 
Korean National Health and Nutrition Examination Sur-
vey  [140, 141] .  Vegetarian and vegan diets are commonly 
followed not only in India but also in other Asian coun-
tries and have recently gained popularity particularly 
among young women of childbearing age  [142–145] . 
Vegetarian diets provide very little, and vegan diets pro-
vide basically no, preformed LC-PUFA. DHA supple-
mentation is advisable, and vegetarian sources of DHA 
from algal oils are available.
 A recent review evaluated the essential fatty acid in-
takes and status of pregnant and lactating women, in-
fants, and children in developing countries and reported 
on findings from Asian countries  [146] .
 In pregnant women, the lowest DHA intakes were re-
ported in India in the third trimester of pregnancy at only 
11 mg  [27] , and in Bangladesh the DHA intake was only 
30 mg/day  [147] .
 The mean concentration of DHA in breast milk is 
quite variable in Asian countries where there is data avail-
able. Some countries have reported lower levels of DHA 
in breast milk, e.g. 0.23% in Nepal  [148] , and 0.30% in 
Bangladesh  [147] , whereas higher DHA levels than the 
approximately 0.3% typically found in breast milk in 
Western countries  [149] were reported in the Philippines 
(0.74 ± 0.05%) and a coastal area of Southeastern China 
(0.61 ± 0.46%)  [150] and about 1% was reported in Japan 
 [151] . These data reflect that the DHA content in human 
milk directly responds to the maternal dietary DHA in-
take  [47] .
 Very few studies have reported intake or status data 
of infants from Asian countries, and intakes vary signifi-
cantly across the region and within countries. In 
 Bangladesh, the total fat intakes were extremely low at 
19.5% of energy in breast-fed children and only 12.7% of 
energy in non-breast-fed children at 24–35 months of age 
 [147] , whereas in children aged 1–3 years in rural areas 
from the Yunnan Province in China the mean fat intake 
was 24 ± 7% of energy  [152] .
 Fig. 1. A marked decrease in the average consumption of fish and 
shellfish, along with an increase in meat intake, occurred in Japan 
during a period of about 20 years and resulted in a marked de-
creased in the dietary supply of DHA as well as in the dietary DHA-
to-AA ratio. Drawn from data of the Ministry of Health, Labour, 
and Welfare, Japanese Government  [139] . 
 Fig. 2. The intake of meat is particularly high and that of fish and 
shellfish is particularly low among younger women of childbearing 
age in Japan. Drawn from data of the Ministry of Health, Labour, 
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 Only 2 studies reported status data of infants and chil-
dren from Asian countries. Low DHA levels in RBC were 
reported in Pakistani infants, corresponding to a low 
DHA content in maternal milk  [153] . In an intervention 
study, the baseline fatty acids statuses of 6-month-old 
Cambodian and Italian infants were compared. 
 Cambodian infants had lower baseline levels of LA, com-
parable ALA levels, and higher levels of AA + EPA + 
DHA in blood compared to their Italian counterparts 
 [154] . Subsequent multiple micronutrient supplementa-
tion in those Cambodian infants resulted in significantly 
higher levels of DHA at 18 months of age compared to 
infants in the other intervention groups who received 
only iron-folic acid or placebo, respectively.
 Conclusions and Recommendations 
 This review revealed a general scarcity of data on n–3 
LC-PUFA supply and benefits in Asian populations. Fu-
ture research should include this region, acknowledging 
its large variety of people and dietary habits. With many 
countries experiencing a rapid nutritional transition, fu-
ture research should include indicators of chronic dis-
eases such as gestational diabetes and programming ef-
fects on future CVD risk factors.
 Since the responses to supplementation are likely to 
depend on current intakes and on nutritional status, fu-
ture research evaluating the benefits of LC-PUFA supple-
mentation should control for baseline nutritional status 
and intakes, as well as genetic variation, e.g. in the  FADS 
genotype. Studies evaluating child development should 
use task-specific, sensitive tests focusing on areas likely to 
benefit from DHA and AA supplementation, including, 
for example, sustained attention and memory recogni-
tion.
 Recent evidence indicates that n–3 LC-PUFA sup-
plementation during pregnancy reduces the risk of ear-
ly preterm birth prior to 34 weeks of gestation, which 
would predict a major benefit for infant morbidity and 
mortality. It is recommended that pregnant women 
should aim to achieve an added minimum average dai-
ly supply of 200 mg DHA over and above the intake 
level recommended for adult general health, resulting 
in a total DHA intake of at least 300 mg/day. Based on 
the comparison of studies with different dosages, it 
seems possible that higher intakes (600–800 mg DHA/
day) may provide greater protection than lower dos-
ages, but direct comparative dose-effect evaluations are 
not available.
 Some but not all studies evaluating the effects of 
DHA or EPA + DHA supplementation in pregnant and 
lactating women and in term infants indicate possible 
beneficial effects on later child visual and cognitive and 
emotional development. The LC-PUFA supply and fish 
intake in pregnancy and infancy seem to positively af-
fect the development of immune responses involved in 
allergic reactions, and reduce the risk of allergic diseas-
es (asthma and eczema). Further support for the benefi-
cial effects of early LC-PUFA status on later cognition 
and asthma risk is provided by recent diet-gene interac-
tion studies.
 Breast-feeding is recommended as the preferred choice 
for infant feeding. Breast-feeding women should aim to 
achieve a minimum average daily supply of 200 mg DHA, 
which is expected to result in a milk DHA content of 0.3% 
of fatty acids  [47] . During the first months of life, term 
infants should receive 100 mg DHA/day and 140 mg AA/
day, and hence infant formula should provide at least 
0.3% of fatty acids as DHA along with AA. We recom-
mend a continued supply of 100 mg DHA/day during the 
second 6 months of life. We do not provide quantitative 
advice on AA intake with follow-on formula fed once 
complimentary foods have been introduced due to a lack 
of sufficient data and due to considerable variation in the 
amounts of AA provided by complimentary foods within 
and among countries.
 There are indications of benefits of supplying DHA in 
combination with AA to preterm infants with respect to 
cognitive and visual development and in infants with a 
birth weight <1,250 g with respect to the prevention of 
neurodevelopmental handicaps and chronic lung disease, 
with apparent greater benefits provided by a higher com-
pared to a lower DHA supply (1 vs. 0.35% of the total 
fatty acid intake). For very-low-birth weight infants (birth 
weight <1,500 g), we support the recent recommenda-
tions  [138] that intakes per kilogram per day of DHA 
ranging from 18 to 60 mg and of AA ranging from 18 to 
45 mg are reasonable, and EPA intakes should not exceed 
20 mg EPA; while intakes per kg per day of 55 to 60 mg 
DHA ( ∼ 1% of the total fatty acid intake), along with 35–
45 mg AA ( ∼ 0.6–0.75% of the total fatty acid intake) are 
considered preferable.
 Acknowledgements 
 The authors thank Prof. Sir Peter Gluckman (University of 
Auckland, New Zealand) for facilitating the organization of the 
workshop prior to the DOHaD Conference of 2013 in Singapore, 
and for opening the workshop with a review presentation on the 
 Perinatal LC-PUFA Supply: Systematic 
Review and Recommendations 
Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
75
 1 Vermunt SH, Mensink RP, Simonis AM, 
Hornstra G: Effects of age and dietary n–3 fat-
ty acids on the metabolism of [13C]-alpha-
linolenic acid. Lipids 1999; 34:S127. 
 2 Pawlosky RJ, Hibbeln JR, Novotny JA, Salem 
N Jr: Physiological compartmental analysis of 
alpha-linolenic acid metabolism in adult hu-
mans. J Lipid Res 2001; 42: 1257–1265. 
 3 Brenna JT: Efficiency of conversion of alpha-
linolenic acid to long chain n–3 fatty acids in 
man. Curr Opin Clin Nutr Metab Care 2002; 5: 
 127–132. 
 4 Lattka E, Klopp N, Demmelmair H, Klingler 
M, Heinrich J, Koletzko B: Genetic variations 
in polyunsaturated fatty acid metabolism – 
implications for child health? Ann Nutr 
Metab 2012; 60: 8–17. 
 5 Glaser C, Lattka E, Rzehak P, Steer C, Koletz-
ko B: Genetic variation in polyunsaturated 
fatty acid metabolism and its potential rele-
vance for human development and health. 
Matern Child Nutr 2011; 7(suppl 2):27–40. 
 6 Koletzko B, Lattka E, Zeilinger S, Illig T, Steer 
C: Genetic variants of the fatty acid desaturase 
gene cluster predict amounts of red blood cell 
docosahexaenoic and other polyunsaturated 
fatty acids in pregnant women: findings from 
the Avon Longitudinal Study of Parents and 
Children. Am J Clin Nutr 2011; 93: 211–219. 
 7 Lattka E, Rzehak P, Szabo E, Jakobik V, Weck 
M, Weyermann M, Grallert H, Rothenbacher 
D, Heinrich J, Brenner H, Decsi T, Illig T, Ko-
letzko B: Genetic variants in the fads gene 
cluster are associated with arachidonic acid 
concentrations of human breast milk at 1.5 
and 6 mo postpartum and influence the 
course of milk dodecanoic, tetracosenoic, and 
 trans- 9-octadecenoic acid concentrations 
over the duration of lactation. Am J Clin Nutr 
2011; 93: 382–391. 
 8 Steer CD, Lattka E, Koletzko B, Golding J, 
Hibbeln JR: Maternal fatty acids in pregnan-
cy, FADS polymorphisms, and child intelli-
gence quotient at 8 y of age. Am J Clin Nutr 
2013; 98: 1575–1582. 
 9 Uauy R, Castillo C: Lipid requirements of in-
fants: implications for nutrient composition 
of fortified complementary foods. J Nutr 
2003; 133: 2962S–2972S. 
 10 Uauy R, Dangour AD: Fat and fatty acid re-
quirements and recommendations for infants 
of 0–2 years and children of 2–18 years. Ann 
Nutr Metab 2009; 55: 76–96. 
 11 Koletzko B, Cetin I, Brenna JT; Perinatal Lip-
id Intake Working Group; Child Health 
Foundation; Diabetic Pregnancy Study 
Group; European Association of Perinatal 
Medicine; European Society for Clinical Nu-
trition and Metabolism; European Society for 
Paediatric Gastroenterology Hepatology and 
Nutrition; International Federation of Pla-
centa Associations; International Society for 
the Study of Fatty Acids and Lipids: Dietary 
fat intakes for pregnant and lactating women. 
Br J Nutr 2007; 98: 873–877. 
 12 Koletzko B, Lien E, Agostoni C, Bohles H, 
Campoy C, Cetin I, Decsi T, Dudenhausen 
JW, Dupont C, Forsyth S, Hoesli I, Holzgreve 
W, Lapillonne A, Putet G, Secher NJ, Sy-
monds M, Szajewska H, Willatts P, Uauy R: 
The roles of long-chain polyunsaturated fatty 
acids in pregnancy, lactation and infancy: re-
view of current knowledge and consensus 
recommendations. J Perinat Med 2008; 36: 
 5–14. 
 13 Adu-Afarwuah S, Lartey A, Brown KH, Zlot-
kin S, Briend A, Dewey KG: Home fortifica-
tion of complementary foods with micronu-
trient supplements is well accepted and has 
positive effects on infant iron status in Ghana. 
Am J Clin Nutr 2008; 87: 929–938. 
 14 Chen CM, Wang YY, Chang SY: Effect of in-
home fortification of complementary feed-
ing on intellectual development of Chinese 
children. Biomed Environ Sci 2010; 23: 83–
91. 
 15 Ramakrishnan U, Stein AD, Parra-Cabrera S, 
Wang M, Imhoff-Kunsch B, Juarez-Marquez 
S, Rivera J, Martorell R: Effects of docosa-
hexaenoic acid supplementation during preg-
nancy on gestational age and size at birth: ran-
domized, double-blind, placebo-controlled 
trial in Mexico. Food Nutr Bull 2010; 31:S108–
S116. 
 16 Su KP, Huang SY, Chiu TH, Huang KC, 
Huang CL, Chang HC, Pariante CM: Ome-
ga-3 fatty acids for major depressive disorder 
during pregnancy: results from a randomized, 
double-blind, placebo-controlled trial. J Clin 
Psychiatry 2008; 69: 644–651. 
 17 Imhoff-Kunsch B, Briggs V, Goldenberg T, 
Ramakrishnan U: Effect of n–3 long-chain 
polyunsaturated fatty acid intake during 
pregnancy on maternal, infant, and child 
health outcomes: a systematic review. Paedi-
atr Perinat Epidemiol 2012; 26(suppl 1):91–
107. 
 18 Szajewska H, Horvath A, Koletzko B: Effect of 
n–3 long-chain polyunsaturated fatty acid 
supplementation of women with low-risk 
pregnancies on pregnancy outcomes and 
growth measures at birth: a meta-analysis of 
randomized controlled trials. Am J Clin Nutr 
2006; 83: 1337–1344. 
 19 Makrides M, Duley L, Olsen SF: Marine oil, 
and other prostaglandin precursor, supple-
mentation for pregnancy uncomplicated by 
pre-eclampsia or intrauterine growth restric-
tion. Cochrane Database Syst Rev 2006; 
 3:CD003402. 
 20 Horvath A, Koletzko B, Szajewska H: Effect of 
supplementation of women in high-risk preg-
nancies with long-chain polyunsaturated fatty 
acids on pregnancy outcomes and growth mea-
sures at birth: a meta-analysis of randomized 
controlled trials. Br J Nutr 2007; 98: 253–259. 
 References 
role of nutrition in the developmental origins of adult health. 
Thanks also go to Felicitas Maier (Ludwig Maximilians University 
of Munich, Germany) for her dedicated help and support in orga-
nizing the consensus meeting and for her contribution to the elec-
tronic literature search.
 The development of this publication was made possible by par-
tial financial support from the Commission of the European Com-
munity, the specific RTD Program Quality of Life and Manage-
ment of Living Resources, within the 7th Framework Program, 
research grant No. FP7/2007–13 (EarlyNutrition Project; project-
earlynutrition.eu), and European Research Council Advanced 
Grant ERC-2012-AdG – No. 322605 META-GROWTH. This pa-
per does not necessarily reflect the views of the Commission and 
in no way anticipates the future policy in this area. An additional 
unconditional grant was provided to the charitable ENA (www.
early-nutrition.org) by DSM Nutritional Products AG, Kaise-
raugst, Switzerland.
 Disclosure Statement 
 Christopher Boey, Cristina Campoy, Namsoo Chang, Sadhana 
Joshi, Christine Prell, Maria Antonia Guillermo-Tuazon, Quak, 
Damayanti Rusli Sjarif, and Sarayut Supapannachart report no con-
flicts of interest. Susan E. Carlson has received financial support 
from DSM, Mead Johnson Nutrition, Wyeth Nutrition, and Se-
quoia. Berthold Koletzko is a member of the National Breastfeeding 
Committee and tends to be biased towards breast-feeding. The Lud-
wig Maximilians University of Munich and its employee Berthold 
Koletzko have received support for scientific and educational ac-
tivities from Abbott, Danone, DSM, Fonterra, Hipp, Mead Johnson, 
and Nestlé, predominantly as part of publically funded research 
projects with support of the European Commission or German gov-
ernmental research granting agencies. Saskia Osendarp worked for 
Unilever until January 2012. Yuichiro Yamashiro has received re-
search support from Yakult Honsha Co., Ltd., Tokyo, Japan. 
 Koletzko   et al. Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
76
 21 Much D, Brunner S, Vollhardt C, Schmid D, 
Sedlmeier EM, Bruderl M, Heimberg E, 
Bartke N, Boehm G, Bader BL, Amann-Gas-
sner U, Hauner H: Effect of dietary interven-
tion to reduce the n–6/n–3 fatty acid ratio on 
maternal and fetal fatty acid profile and its re-
lation to offspring growth and body composi-
tion at 1 year of age. Eur J Clin Nutr 2013; 67: 
 282–288. 
 22 Carlson SE, Colombo J, Gajewski BJ, Gus-
tafson KM, Mundy D, Yeast J, Georgieff MK, 
Markley LA, Kerling EH, Shaddy DJ: DHA 
supplementation and pregnancy outcomes. 
Am J Clin Nutr 2013; 97: 808–815. 
 23 Courville AB, Harel O, Lammi-Keefe CJ: 
Consumption of a DHA-containing func-
tional food during pregnancy is associated 
with lower infant ponderal index and cord 
plasma insulin concentration. Br J Nutr 2011; 
 106: 208–212. 
 24 Makrides M, Gibson RA, McPhee AJ, Yelland 
L, Quinlivan J, Ryan P; DOMInO Investiga-
tive Team: Effect of DHA supplementation 
during pregnancy on maternal depression 
and neurodevelopment of young children: a 
randomized controlled trial. JAMA 2010; 304: 
 1675–1683. 
 25 Harper M, Thom E, Klebanoff MA, Thorp J, 
Sorokin Y, Varner MW, Wapner RJ, Caritis 
SN, Iams JD, Carpenter MW, Peaceman AM, 
Mercer BM, Sciscione A, Rouse DJ, Ramin 
SM, Anderson GD; Eunice Kennedy Shriver 
National Institute of Child Health and Hu-
man DevelopmentMaternal-Fetal Medicine 
Units Network: Omega-3 fatty acid supple-
mentation to prevent recurrent preterm birth 
a randomized controlled trial. Obstet Gynecol 
2010; 115: 234–242. 
 26 Zhou SJ, Yelland L, McPhee AJ, Quinlivan J, 
Gibson RA, Makrides M: Fish-oil supplemen-
tation in pregnancy does not reduce the risk 
of gestational diabetes or preeclampsia. Am J 
Clin Nutr 2012; 95: 1378–1384. 
 27 Muthayya S, Dwarkanath P, Thomas T, Ram-
prakash S, Mehra R, Mhaskar A, Mhaskar R, 
Thomas A, Bhat S, Vaz M, Kurpad AV: The 
effect of fish and omega-3 LCPUFA intake on 
low birth weight in Indian pregnant women. 
Eur J Clin Nutr 2009; 63: 340–346. 
 28 Lederman SA, Jones RL, Caldwell KL, Rauh 
V, Sheets SE, Tang D, Viswanathan S, Becker 
M, Stein JL, Wang RY, Perera FP: Relation be-
tween cord blood mercury levels and early 
child development in a world trade center co-
hort. Environ Health Perspect 2008;  116: 
 1085–1091. 
 29 Oken E, Radesky JS, Wright RO, Bellinger 
DC, Amarasiriwardena CJ, Kleinman KP, Hu 
H, Gillman MW: Maternal fish intake during 
pregnancy, blood mercury levels, and child 
cognition at age 3 years in a US cohort. Am J 
Epidemiol 2008; 167: 1171–1181. 
 30 Gale CR, Marriott LD, Martyn CN, Limond 
J, Inskip HM, Godfrey KM, Law CM, Cooper 
C, West C, Robinson SM: Breastfeeding, the 
use of docosahexaenoic acid-fortified formu-
las in infancy and neuropsychological func-
tion in childhood. Arch Dis Child 2010; 95: 
 174–179. 
 31 Gould JF, Smithers LG, Makrides M: The ef-
fect of maternal omega-3 (n–3) LCPUFA sup-
plementation during pregnancy on early 
childhood cognitive and visual development: 
a systematic review and meta-analysis of ran-
domized controlled trials. Am J Clin Nutr 
2013; 97: 531–544. 
 32 Campoy C, Escolano-Margarit MV, Ramos 
R, Parrilla-Roure M, Csabi G, Beyer J, 
Ramirez-Tortosa MC, Molloy AM, Decsi T, 
Koletzko BV: Effects of prenatal fish-oil and 
5-methyltetrahydrofolate supplementation 
on cognitive development of children at 6.5 y 
of age. Am J Clin Nutr 2011; 94: 1880S–1888S. 
 33 Campoy C, Escolano-Margarit MV, Anjos T, 
Szajewska H, Uauy R: Omega 3 fatty acids on 
child growth, visual acuity and neurodevel-
opment. Br J Nutr 2012; 107(suppl 2):S85–
S106. 
 34 Stein AD, Wang M, Rivera JA, Martorell R, 
Ramakrishnan U: Auditory- and visual-
evoked potentials in Mexican infants are not 
affected by maternal supplementation with 
400 mg/d docosahexaenoic acid in the second 
half of pregnancy. J Nutr 2012; 142: 1577–
1581. 
 35 Smithers LG, Gibson RA, Makrides M: Ma-
ternal supplementation with docosahexaeno-
ic acid during pregnancy does not affect early 
visual development in the infant: a random-
ized controlled trial. Am J Clin Nutr 2011; 93: 
 1293–1299. 
 36 Gustafson KM, Carlson SE, Colombo J, Yeh 
HW, Shaddy DJ, Li S, Kerling EH: Effects of 
docosahexaenoic acid supplementation dur-
ing pregnancy on fetal heart rate and variabil-
ity: a randomized clinical trial. Prostaglan-
dins Leukot Essent Fatty Acids 2013; 88: 331–
338. 
 37 Judge MP, Cong X, Harel O, Courville AB, 
Lammi-Keefe CJ: Maternal consumption of a 
DHA-containing functional food benefits in-
fant sleep patterning: an early neurodevelop-
mental measure. Early Hum Dev 2012; 88: 
 531–537. 
 38 Kohlboeck G, Glaser C, Tiesler C, Demmel-
mair H, Standl M, Romanos M, Koletzko B, 
Lehmann I, Heinrich J, LISAplus Study 
Group: Effect of fatty acid status in cord blood 
serum on children’s behavioral difficulties at 
10 y of age: results from the LISAplus Study. 
Am J Clin Nutr 2011; 94: 1592–1599. 
 39 van Goor SA, Dijck-Brouwer DA, Erwich JJ, 
Schaafsma A, Hadders-Algra M: The influ-
ence of supplemental docosahexaenoic and 
arachidonic acids during pregnancy and lac-
tation on neurodevelopment at eighteen 
months. Prostaglandins Leukot Essent Fatty 
Acids 2011; 84: 139–146. 
 40 Helland IB, Smith L, Blomen B, Saarem K, 
Saugstad OD, Drevon CA: Effect of supple-
menting pregnant and lactating mothers with 
n–3 very-long-chain fatty acids on children’s 
IQ and body mass index at 7 years of age. Pe-
diatrics 2008; 122:e472–e479. 
 41 Delgado-Noguera MF, Calvache JA, Bonfill 
Cosp X: Supplementation with long chain 
polyunsaturated fatty acids (LCPUFA) to 
breastfeeding mothers for improving child 
growth and development. Cochrane Database 
Syst Rev 2010, p CD007901. 
 42 Jensen CL, Voigt RG, Llorente AM, Peters SU, 
Prager TC, Zou YL, Rozelle JC, Turcich MR, 
Fraley JK, Anderson RE, Heird WC: Effects of 
early maternal docosahexaenoic acid intake 
on neuropsychological status and visual acu-
ity at five years of age of breast-fed term in-
fants. J Pediatr 2010; 157: 900–905. 
 43 Jensen CL, Voigt RG, Prager TC, Zou YL, 
Fraley JK, Rozelle JC, Turcich MR, Llorente 
AM, Anderson RE, Heird WC: Effects of ma-
ternal docosahexaenoic acid intake on visual 
function and neurodevelopment in breastfed 
term infants. Am J Clin Nutr 2005; 82: 125–
132. 
 44 Cheatham CL, Nerhammer AS, Asserhoj M, 
Michaelsen KF, Lauritzen L: Fish oil supple-
mentation during lactation: effects on cogni-
tion and behavior at 7 years of age. Lipids 
2011; 46: 637–645. 
 45 Steer CD, Davey Smith G, Emmett PM, Hib-
beln JR, Golding J: FADS2 polymorphisms 
modify the effect of breastfeeding on child IQ. 
PLoS One 2010; 5:e11570. 
 46 Morales E, Bustamante M, Gonzalez JR, Gux-
ens M, Torrent M, Mendez M, Garcia-Este-
ban R, Julvez J, Forns J, Vrijheid M, Molto-
Puigmarti C, Lopez-Sabater C, Estivill X, Su-
nyer J: Genetic variants of the FADS gene 
cluster and ELOVL gene family, colostrums 
LC-PUFA levels, breastfeeding, and child 
cognition. PLoS One 2011; 6:e17181. 
 47 Fidler N, Sauerwald T, Pohl A, Demmelmair 
H, Koletzko B: Docosahexaenoic acid transfer 
into human milk after dietary supplementa-
tion: a randomized clinical trial. J Lipid Res 
2000; 41: 1376–1383. 
 48 Del Prado M, Villalpando S, Elizondo A, Ro-
driguez M, Demmelmair H, Koletzko B: Con-
tribution of dietary and newly formed arachi-
donic acid to human milk lipids in women 
eating a low-fat diet. Am J Clin Nutr 2001; 74: 
 242–247. 
 49 Klemens CM, Berman DR, Mozurkewich EL: 
The effect of perinatal omega-3 fatty acid sup-
plementation on inflammatory markers and 
allergic diseases: a systematic review. BJOG 
2011; 118: 916–925. 
 50 Urwin HJ, Miles EA, Noakes PS, Kremmyda 
LS, Vlachava M, Diaper ND, Perez-Cano FJ, 
Godfrey KM, Calder PC, Yaqoob P: Salmon 
consumption during pregnancy alters fatty 
acid composition and secretory IgA concen-
tration in human breast milk. J Nutr 2012; 
 142: 1603–1610. 
 51 Noakes PS, Vlachava M, Kremmyda LS, Dia-
per ND, Miles EA, Erlewyn-Lajeunesse M, 
Williams AP, Godfrey KM, Calder PC: In-
creased intake of oily fish in pregnancy: effects 
on neonatal immune responses and on clini-
cal outcomes in infants at 6 mo. Am J Clin 
Nutr 2012; 95: 395–404. 
 Perinatal LC-PUFA Supply: Systematic 
Review and Recommendations 
Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
77
 52 Furuhjelm C, Jenmalm MC, Falth-Magnus-
son K, Duchen K: Th1 and Th2 chemokines, 
vaccine-induced immunity, and allergic dis-
ease in infants after maternal omega-3 fatty 
acid supplementation during pregnancy and 
lactation. Pediatr Res 2011; 69: 259–264. 
 53 Krauss-Etschmann S, Hartl D, Rzehak P, 
Heinrich J, Shadid R, Del Carmen Ramirez-
Tortosa M, Campoy C, Pardillo S, Schendel 
DJ, Decsi T, Demmelmair H, Koletzko BV; 
Nutraceuticals for Healthier Life Study 
Group: Decreased cord blood IL-4, IL-13, 
and CCR4 and increased TGF-beta levels af-
ter fish oil supplementation of pregnant 
women. J Allergy Clin Immunol 2008; 121: 
 464–470.e466. 
 54 Warstedt K, Furuhjelm C, Duchen K, Falth-
Magnusson K, Fageras M: The effects of ome-
ga-3 fatty acid supplementation in pregnancy 
on maternal eicosanoid, cytokine, and chemo-
kine secretion. Pediatr Res 2009; 66: 212–217. 
 55 Palmer DJ, Sullivan T, Gold MS, Prescott SL, 
Heddle R, Gibson RA, Makrides M: Effect of 
n–3 long chain polyunsaturated fatty acid 
supplementation in pregnancy on infants’ al-
lergies in first year of life: randomised con-
trolled trial. BMJ 2012; 344:e184. 
 56 Furuhjelm C, Warstedt K, Larsson J, Fredriks-
son M, Bottcher MF, Falth-Magnusson K, 
Duchen K: Fish oil supplementation in preg-
nancy and lactation may decrease the risk of 
infant allergy. Acta Paediatr 2009; 98: 1461–
1467. 
 57 Olsen SF, Osterdal ML, Salvig JD, Mortensen 
LM, Rytter D, Secher NJ, Henriksen TB: Fish 
oil intake compared with olive oil intake in 
late pregnancy and asthma in the offspring: 
16 y of registry-based follow-up from a ran-
domized controlled trial. Am J Clin Nutr 
2008; 88: 167–175. 
 58 Imhoff-Kunsch B, Stein AD, Martorell R, Par-
ra-Cabrera S, Romieu I, Ramakrishnan U: 
Prenatal docosahexaenoic acid supplementa-
tion and infant morbidity: randomized con-
trolled trial. Pediatrics 2011; 128:e505–e512. 
 59 Furuhjelm C, Warstedt K, Fageras M, Falth-
Magnusson K, Larsson J, Fredriksson M, 
Duchen K: Allergic disease in infants up to 
2 years of age in relation to plasma omega-3 
fatty acids and maternal fish oil supplementa-
tion in pregnancy and lactation. Pediatr Al-
lergy Immunol 2011; 22: 505–514. 
 60 Granot E, Jakobovich E, Rabinowitz R, Levy 
P, Schlesinger M: DHA supplementation dur-
ing pregnancy and lactation affects infants’ 
cellular but not humoral immune response. 
Mediators Inflamm 2011; 2011: 493925. 
 61 Linnamaa P, Savolainen J, Koulu L, Tuomas-
jukka S, Kallio H, Yang B, Vahlberg T, Tah-
vonen R: Blackcurrant seed oil for prevention 
of atopic dermatitis in newborns: a random-
ized, double-blind, placebo-controlled trial. 
Clin Exp Allergy 2010; 40: 1247–1255. 
 62 Sausenthaler S, Koletzko S, Schaaf B, Lehm-
ann I, Borte M, Herbarth O, von Berg A, 
Wichmann HE, Heinrich J, Group LS: Mater-
nal diet during pregnancy in relation to ec-
zema and allergic sensitization in the off-
spring at 2 y of age. Am J Clin Nutr 2007; 85: 
 530–537. 
 63 Calvani M, Alessandri C, Sopo SM, Panetta V, 
Pingitore G, Tripodi S, Zappala D, Zicari AM: 
Consumption of fish, butter and margarine 
during pregnancy and development of aller-
gic sensitizations in the offspring: role of ma-
ternal atopy. Pediatr Allergy Immunol 2006; 
 17: 94–102. 
 64 Willers SM, Devereux G, Craig LC, McNeill 
G, Wijga AH, Abou El-Magd W, Turner SW, 
Helms PJ, Seaton A: Maternal food consump-
tion during pregnancy and asthma, respira-
tory and atopic symptoms in 5-year-old chil-
dren. Thorax 2007; 62: 773–779. 
 65 Romieu I, Torrent M, Garcia-Esteban R, Fer-
rer C, Ribas-Fito N, Anto JM, Sunyer J: Ma-
ternal fish intake during pregnancy and atopy 
and asthma in infancy. Clin Exp Allergy 2007; 
 37: 518–525. 
 66  Standl M, Sausenthaler S, Lattka E, Koletzko 
S, Bauer CP, Wichmann HE, von Berg A, 
Berdel D, Krämer U, Schaaf B, Lehmann I, 
Herbarth O, Klopp N, Koletzko B, Heinrich J; 
GINIplus and LISAplus Study Group: FADS 
gene cluster modulates the effect of breast-
feeding on asthma. Results from the GINIplus 
and LISAplus studies. Allergy 2012;67:83–90. 
 67 Lee HS, Barraza-Villarreal A, Hernandez-
Vargas H, Sly PD, Biessy C, Ramakrishnan 
U, Romieu I, Herceg Z: Modulation of DNA 
methylation states and infant immune sys-
tem by dietary supplementation with ome-
ga-3 PUFA during pregnancy in an interven-
tion study. Am J Clin Nutr 2013; 98: 480–487. 
 68 Wojcicki JM, Heyman MB: Maternal ome-
ga-3 fatty acid supplementation and risk for 
perinatal maternal depression. J Matern Fetal 
Neonatal Med 2011; 24: 680–686. 
 69 Mozurkewich EL, Clinton CM, Chilimigras 
JL, Hamilton SE, Allbaugh LJ, Berman DR, 
Marcus SM, Romero VC, Treadwell MC, 
Keeton KL, Vahratian AM, Schrader RM, Ren 
J, Djuric Z: The Mothers, Omega-3, and Men-
tal Health Study: a double-blind, randomized 
controlled trial. Am J Obstet Gynecol 2013; 
 208: 313.e311–313.e319. 
 70 Doornbos B, van Goor SA, Dijck-Brouwer 
DAJ, Schaafsma A, Korf J, Muskiet FAJ: Sup-
plementation of a low dose of DHA or DHA 
plus AA does not prevent peripartum depres-
sive symptoms in a small population based 
sample. Prog Neuropsychopharmacol Biol 
Psychiatry 2009; 33: 49–52. 
 71 Hauner H, Much D, Vollhardt C, Brunner S, 
Schmid D, Sedlmeier EM, Heimberg E, 
Schuster T, Zimmermann A, Schneider KT, 
Bader BL, Amann-Gassner U: Effect of reduc-
ing the n–6:n–3 long-chain PUFA ratio dur-
ing pregnancy and lactation on infant adipose 
tissue growth within the first year of life: an 
open-label randomized controlled trial. Am J 
Clin Nutr 2012; 95: 383–394. 
 72 Rodriguez G, Iglesia I, Bel-Serrat S, Moreno 
LA: Effect of n–3 long chain polyunsaturated 
fatty acids during the perinatal period on 
 later body composition. Br J Nutr 2012; 
 107(suppl 2):S117–S128. 
 73 Martinez-Victoria E, Yago MD: Omega 3 
polyunsaturated fatty acids and body weight. 
Br J Nutr 2012; 107(suppl 2):S107–S116. 
 74 Muhlhausler BS, Gibson RA, Makrides M: Ef-
fect of long-chain polyunsaturated fatty acid 
supplementation during pregnancy or lacta-
tion on infant and child body composition: a 
systematic review. Am J Clin Nutr 2010; 92: 
 857–863. 
 75 Hauner H, Brunner S, Amann-Gassner U: 
The role of dietary fatty acids for early human 
adipose tissue growth. Am J Clin Nutr 2013; 
 98: 549S–555S. 
 76 Asserhoj M, Nehammer S, Matthiessen J, Mi-
chaelsen KF, Lauritzen L: Maternal fish oil 
supplementation during lactation may ad-
versely affect long-term blood pressure, en-
ergy intake, and physical activity of 7-year-old 
boys. J Nutr 2009; 139: 298–304. 
 77 Rytter D, Bech BH, Christensen JH, Schmidt 
EB, Henriksen TB, Olsen SF: Intake of fish oil 
during pregnancy and adiposity in 19-y-old 
offspring: follow-up on a randomized con-
trolled trial. Am J Clin Nutr 2011; 94: 701–
708. 
 78 Rytter D, Christensen JH, Bech BH, Schmidt 
EB, Henriksen TB, Olsen SF: The effect of ma-
ternal fish oil supplementation during the last 
trimester of pregnancy on blood pressure, 
heart rate and heart rate variability in the 
19-year-old offspring. Br J Nutr 2012; 108: 
 1475–1483. 
 79 Rytter D, Schmidt EB, Bech BH, Christensen 
JH, Henriksen TB, Olsen SF: Fish oil supple-
mentation during late pregnancy does not in-
fluence plasma lipids or lipoprotein levels in 
young adult offspring. Lipids 2011; 46: 1091–
1099. 
 80 Franke C, Demmelmair H, Decsi T, Campoy 
C, Cruz M, Molina-Font JA, Mueller K, Ko-
letzko B: Influence of fish oil or folate supple-
mentation on the time course of plasma redox 
markers during pregnancy. Br J Nutr 2010; 
 103: 1648–1656. 
 81 Garcia-Rodriguez CE, Helmersson-Karlqvist 
J, Mesa MD, Miles EA, Noakes PS, Vlachava 
M, Kremmyda LS, Diaper ND, Godfrey KM, 
Calder PC, Gil A, Basu S: Does increased in-
take of salmon increase markers of oxidative 
stress in pregnant women? The Salmon in 
Pregnancy Study. Antiox Redox Signal 2011; 
 15: 2819–2823. 
 82 Simmer K, Patole SK, Rao SC: Long-chain 
polyunsaturated fatty acid supplementation 
in infants born at term. Cochrane Database 
Syst Rev 2011;12:CD000376. 
 83 Qawasmi A, Landeros-Weisenberger A, 
Bloch MH: Meta-analysis of LCPUFA supple-
mentation of infant formula and visual acuity. 
Pediatrics 2013; 131:e262–e272. 
 84 Qawasmi A, Landeros-Weisenberger A, 
Leckman JF, Bloch MH: Meta-analysis of 
long-chain polyunsaturated fatty acid supple-
mentation of formula and infant cognition. 
Pediatrics 2012; 129: 1141–1149. 
 Koletzko   et al. Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
78
 85 Drover JR, Hoffman DR, Castaneda YS, Mo-
rale SE, Garfield S, Wheaton DH, Birch EE: 
Cognitive function in 18-month-old term in-
fants of the DIAMOND study: a randomized, 
controlled clinical trial with multiple dietary 
levels of docosahexaenoic acid. Early Hum 
Dev 2011; 87: 223–230. 
 86 Birch EE, Carlson SE, Hoffman DR, Fitzger-
ald-Gustafson KM, Fu VL, Drover JR, Cas-
taneda YS, Minns L, Wheaton DK, Mundy 
D, Marunycz J, Diersen-Schade DA: The 
DIAMOND (DHA Intake And Measure-
ment Of Neural Development) study: a dou-
ble-masked, randomized controlled clinical 
trial of the maturation of infant visual acuity 
as a function of the dietary level of docosa-
hexaenoic acid. Am J Clin Nutr 2010; 91: 
 848–859. 
 87 Meldrum SJ, D’Vaz N, Simmer K, Dunstan 
JA, Hird K, Prescott SL: Effects of high-dose 
fish oil supplementation during early infancy 
on neurodevelopment and language: a ran-
domised controlled trial. Br J Nutr 2012; 108: 
 1443–1454. 
 88 Agostoni C, Zuccotti GV, Radaelli G, Besana 
R, Podesta A, Sterpa A, Rottoli A, Riva E, 
Giovannini M: Docosahexaenoic acid supple-
mentation and time at achievement of gross 
motor milestones in healthy infants: a ran-
domized, prospective, double-blind, placebo-
controlled trial. Am J Clin Nutr 2009; 89: 64–
70. 
 89 Colombo J, Carlson SE, Cheatham CL, 
Shaddy DJ, Kerling EH, Thodosoff JM, Gus-
tafson KM, Brez C: Long-term effects of 
LCPUFA supplementation on childhood 
cognitive outcomes. Am J Clin Nutr 2013; 
 98: 403–412. 
 90 Willatts P, Forsyth S, Agostoni C, Casaer P, 
Riva E, Boehm G: Effects of long-chain PUFA 
supplementation in infant formula on cogni-
tive function in later childhood. Am J Clin 
Nutr 2013; 98: 536S–542S. 
 91 de Jong C, Kikkert HK, Fidler V, Hadders-
Algra M: Effects of long-chain polyunsaturat-
ed fatty acid supplementation of infant for-
mula on cognition and behaviour at 9 years of 
age. Dev Med Child Neurol 2012; 54: 1102–
1108. 
 92 Drover JR, Felius J, Hoffman DR, Castaneda 
YS, Garfield S, Wheaton DH, Birch EE: A ran-
domized trial of DHA intake during infancy: 
school readiness and receptive vocabulary at 
2–3.5 years of age. Early Hum Dev 2012; 88: 
 885–891. 
 93 Rosenfeld E, Beyerlein A, Hadders-Algra M, 
Kennedy K, Singhal A, Fewtrell M, Lucas A, 
Koletzko B, von Kries R: IPD meta-analysis 
shows no effect of LC-PUFA supplementa-
tion on infant growth at 18 months. Acta Pae-
diatr 2009; 98: 91–97. 
 94 Makrides M, Gibson RA, Udell T, Ried K; In-
ternational LCPUFA Investigators: Supple-
mentation of infant formula with long-chain 
polyunsaturated fatty acids does not influence 
the growth of term infants. Am J Clin Nutr 
2005; 81: 1094–1101. 
  95 Vivatvakin B, Mahayosnond A, Theamboon-
lers A, Steenhout PG, Conus NJ: Effect of a 
whey-predominant starter formula contain-
ing LCPUFAs and oligosaccharides (FOS/
GOS) on gastrointestinal comfort in infants. 
Asia Pac J Clin Nutr 2010; 19: 473–480. 
  96 Rzehak P, Koletzko S, Koletzko B, Sausen-
thaler S, Reinhardt D, Grubl A, Bauer CP, 
Kramer U, Bollrath C, von Berg A, Berdel D, 
Wichmann HE, Heinrich J; GINI Study 
Group: Growth of infants fed formula rich in 
canola oil (low erucic acid rapeseed oil). Clin 
Nutr 2011; 30: 339–345. 
  97 Gibson RA, Barclay D, Marshall H, Moulin J, 
Maire JC, Makrides M: Safety of supplement-
ing infant formula with long-chain polyun-
saturated fatty acids and  Bifidobacterium lac-
tis in term infants: a randomised controlled 
trial. Br J Nutr 2009; 101: 1706–1713. 
  98 Larnkjaer A, Hoppe C, Molgaard C, Mi-
chaelsen KF: The effects of whole milk and 
infant formula on growth and IGF-I in late 
infancy. Eur J Clin Nutr 2009; 63: 956–963. 
  99 de Jong C, Boehm G, Kikkert HK, Hadders-
Algra M: The Groningen LCPUFA Study: no 
effect of short-term postnatal long-chain 
polyunsaturated fatty acids in healthy term 
infants on cardiovascular and anthropomet-
ric development at 9 years. Pediatr Res 2011; 
 70: 411–416. 
 100 Foolad N, Brezinski EA, Chase EP, Arm-
strong AW: Effect of nutrient supplementa-
tion on atopic dermatitis in children: a sys-
tematic review of probiotics, prebiotics, for-
mula, and fatty acids. JAMA Dermatol 2013; 
 149: 350–355. 
 101 Field CJ, Van Aerde JE, Goruk S, Clandinin 
MT: Effect of feeding a formula supplemented 
with long-chain polyunsaturated fatty acids 
for 14 weeks improves the ex vivo response to 
a mitogen and reduces the response to a soy 
protein in infants at low risk for allergy. J Pe-
diatr Gastroenterol Nutr 2010; 50: 661–669. 
 102 D’Vaz N, Meldrum SJ, Dunstan JA, Lee-Pul-
len TF, Metcalfe J, Holt BJ, Serralha M, Tulic 
MK, Mori TA, Prescott SL: Fish oil supple-
mentation in early infancy modulates devel-
oping infant immune responses. Clin Exp 
Allergy 2012; 42: 1206–1216. 
 103 Birch EE, Khoury JC, Berseth CL, Castaneda 
YS, Couch JM, Bean J, Tamer R, Harris CL, 
Mitmesser SH, Scalabrin DM: The impact of 
early nutrition on incidence of allergic mani-
festations and common respiratory illnesses 
in children. J Pediatr 2010; 156: 902–906, 906.
e901. 
 104 D’Vaz N, Meldrum SJ, Dunstan JA, Martino 
D, McCarthy S, Metcalfe J, Tulic MK, Mori 
TA, Prescott SL: Postnatal fish oil supple-
mentation in high-risk infants to prevent al-
lergy: randomized controlled trial. Pediat-
rics 2012; 130: 674–682. 
 105 Alm B, Aberg N, Erdes L, Mollborg P, Pet-
tersson R, Norvenius SG, Goksor E, Wenn-
ergren G: Early introduction of fish decreas-
es the risk of eczema in infants. Arch Dis 
Child 2009; 94: 11–15. 
 106 Kull I, Bergstrom A, Melen E, Lilja G, van 
Hage M, Pershagen G, Wickman M: Early-
life supplementation of vitamins A and D, 
in water-soluble form or in peanut oil, and 
allergic diseases during childhood. J Aller-
gy Clin Immunol 2006; 118: 1299–1304. 
 107 Colombo J, Carlson SE, Cheatham CL, 
Fitzgerald-Gustafson KM, Kepler A, Doty T: 
Long-chain polyunsaturated fatty acid sup-
plementation in infancy reduces heart rate 
and positively affects distribution of atten-
tion. Pediatr Res 2011; 70: 406–410. 
 108 Pivik RT, Dykman RA, Jing H, Gilchrist JM, 
Badger TM: Early infant diet and the omega 
3 fatty acid DHA: effects on resting cardio-
vascular activity and behavioral develop-
ment during the first half-year of life. Dev 
Neuropsychol 2009; 34: 139–158. 
 109 van der Merwe LF, Moore SE, Fulford AJ, 
Halliday KE, Drammeh S, Young S, Prentice 
AM: Long-chain PUFA supplementation in 
rural African infants: a randomized con-
trolled trial of effects on gut integrity, 
growth, and cognitive development. Am J 
Clin Nutr 2013; 97: 45–57. 
 110 Andersen AD, Michaelsen KF, Hellgren LI, 
Trolle E, Lauritzen L: A randomized con-
trolled intervention with fish oil versus sun-
flower oil from 9 to 18 months of age: explor-
ing changes in growth and skinfold thick-
nesses. Pediatr Res 2011; 70: 368–374. 
 111 Andersen AD, Molbak L, Michaelsen KF, 
Lauritzen L: Molecular fingerprints of the 
human fecal microbiota from 9 to 18 months 
old and the effect of fish oil supplementa-
tion. J Pediatr Gastroenterol Nutr 2011; 53: 
 303–309. 
 112 Ayer JG, Harmer JA, Xuan W, Toelle B, 
Webb K, Almqvist C, Marks GB, Celermajer 
DS: Dietary supplementation with n–3 poly-
unsaturated fatty acids in early childhood: 
effects on blood pressure and arterial struc-
ture and function at age 8 y. Am J Clin Nutr 
2009; 90: 438–446. 
 113 Lauritzen L, Christensen JH, Damsgaard 
CT, Michaelsen KF: The effect of fish oil sup-
plementation on heart rate in healthy  Danish 
infants. Pediatr Res 2008; 64: 610–614. 
 114 Harbild HL, Harslof LB, Christensen JH, Kan-
nass KN, Lauritzen L: Fish oil-supplementa-
tion from 9 to 12 months of age affects infant 
attention in a free-play test and is related to 
change in blood pressure. Prostaglandins Leu-
kot Essent Fatty Acids 2013; 89: 327–333. 
 115 Makrides M, Gibson RA, McPhee AJ, Col-
lins CT, Davis PG, Doyle LW, Simmer K, 
Colditz PB, Morris S, Smithers LG, Willson 
K, Ryan P: Neurodevelopmental outcomes 
of preterm infants fed high-dose docosa-
hexaenoic acid a randomized controlled tri-
al. JAMA 2009; 301: 175–182. 
 116 Atwell K, Collins CT, Sullivan TR, Ryan P, 
Gibson RA, Makrides M, McPhee AJ: Respi-
ratory hospitalisation of infants supple-
mented with docosahexaenoic acid as pre-
term neonates. J Paediatr Child Health 2013; 
 49:E17–E22. 
 Perinatal LC-PUFA Supply: Systematic 
Review and Recommendations 
Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
79
 117 Manley BJ, Makrides M, Collins CT, McPhee 
AJ, Gibson RA, Ryan P, Sullivan TR, Davis PG: 
High-dose docosahexaenoic acid supplemen-
tation of preterm infants: respiratory and al-
lergy outcomes. Pediatrics 2011; 128:e71–e77. 
 118 Collins CT, Makrides M, Gibson RA, 
McPhee AJ, Davis PG, Doyle LW, Simmer K, 
Colditz PB, Morris S, Sullivan TR, Ryan P: 
Pre- and post-term growth in pre-term in-
fants supplemented with higher-dose DHA: 
a randomised controlled trial. Br J Nutr 
2011; 105: 1635–1643. 
 119 Smithers LG, Gibson RA, McPhee A, 
Makrides M: Effect of two doses of docosa-
hexaenoic acid (DHA) in the diet of preterm 
infants on infant fatty acid status: results 
from the DINO trial. Prostaglandins Leukot 
Essent Fatty Acids 2008; 79: 141–146. 
 120 Schulzke SM, Patole SK, Simmer K: Long-
chain polyunsaturated fatty acid supple-
mentation in preterm infants. Cochrane Da-
tabase Syst Rev 2011;2:CD000375. 
 121 Smithers LG, Collins CT, Simmonds LA, 
Gibson RA, McPhee A, Makrides M: Feed-
ing preterm infants milk with a higher dose 
of docosahexaenoic acid than that used in 
current practice does not influence language 
or behavior in early childhood: a follow-up 
study of a randomized controlled trial. Am J 
Clin Nutr 2010; 91: 628–634. 
 122 Isaacs EB, Ross S, Kennedy K, Weaver LT, 
Lucas A, Fewtrell MS: 10-year cognition in 
preterms after random assignment to fatty 
acid supplementation in infancy. Pediatrics 
2011; 128:e890–e898. 
 123 Henriksen C, Haugholt K, Lindgren M, Au-
rvag AK, Ronnestad A, Gronn M, Solberg R, 
Moen A, Nakstad B, Berge RK, Smith L, 
Iversen PO, Drevon CA: Improved cogni-
tive development among preterm infants at-
tributable to early supplementation of hu-
man milk with docosahexaenoic acid and 
arachidonic acid. Pediatrics 2008; 121: 1137–
1145. 
 124 Smithers LG, Gibson RA, McPhee A, 
Makrides M: Higher dose of docosahexae-
noic acid in the neonatal period improves 
visual acuity of preterm infants: results of a 
randomized controlled trial. Am J Clin Nutr 
2008; 88: 1049–1056. 
 125 Field CJ, Thomson CA, Van Aerde JE, Par-
rott A, Euler A, Lien E, Clandinin MT: Low-
er proportion of CD45R0+ cells and defi-
cient interleukin-10 production by formula-
fed infants, compared with human-fed, is 
corrected with supplementation of long-
chain polyunsaturated fatty acids. J Pediatr 
Gastroenterol Nutr 2000; 31: 291–299. 
 126 Kennedy K, Ross S, Isaacs EB, Weaver LT, 
Singhal A, Lucas A, Fewtrell MS: The 10-
year follow-up of a randomised trial of long-
chain polyunsaturated fatty acid supple-
mentation in preterm infants: effects on 
growth and blood pressure. Arch Dis Child 
2010; 95: 588–595. 
 127 Koletzko B, Lien E, Agostoni C, Bohles H, 
Campoy C, Cetin I, Decsi T, Dudenhausen 
JW, Dupont C, Forsyth S, Hoesli I, Hol-
zgreve W, Lapillonne A, Putet G, Secher NJ, 
Symonds M, Szajewska H, Willatts P, Uauy 
R; World Association of Perinatal Medi-
cine Dietary Guidelines Working Group: 
The roles of long-chain polyunsaturated 
fatty acids in pregnancy, lactation and in-
fancy: review of current knowledge and 
consensus recommendations. J Perinat 
Med 2008; 36: 5–14. 
 128 Koletzko B, Cetin I, Brenna JT; Perinatal Lipid 
Intake Working Group; Child Health Foun-
dation, Diabetic Pregnancy Study Group, 
 European Association of Perinatal Medicine; 
European Society for Clinical Nutrition and 
Metabolis; European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition, 
Committee on Nutrition; International Fed-
eration of Placenta Associations; Internation-
al Society for the Study of Fatty Acids and Lip-
ids. Dietary fat intakes for pregnant and lactat-
ing women. Br J Nutr 2007; 98: 873–877. 
 129 ESPGHAN Committee on Nutrition; Agos-
toni C, Braegger C, Decsi T, Kolacek S, Ko-
letzko B, Michaelsen KF, Mihatsch W, 
Moreno LA, Puntis J, Shamir R, Szajewska 
H, Turck D, van Goudoever J: Breast-feed-
ing: a commentary by the ESPGHAN Com-
mittee on Nutrition. J Pediatr Gastroenterol 
Nutr 2009; 49: 112–125. 
 130 EFSA Panel on Dietetic Products, Nutrition, 
and Allergies: Scientific opinion on dietary 
reference values for fats, including saturated 
fatty acids, polyunsaturated fatty acids, 
monounsaturated fatty acids, trans fatty ac-
ids, and cholesterol. EFSA J 2010; 8: 1461–
1468. 
 131 EFSA Panel on Dietetic Products, Nutrition, 
and Allergies: Scientific opinion on nutrient 
requirements and dietary intakes of infants 
and young children in the European Union. 
EFSA J 2013; 11: 3408. 
 132 EFSA Panel on Dietetic Products, Nutrition, 
and Allergies: Draft scientific Opinion on 
the Essential Composition of Infant and Fol-
low-on Formulae. Parma, EFSA, 2014. 
 133 Food and Agriculture Organization of the 
United Nations: Fats and Fatty Acids in 
Human Nutrition: Report of a Joint FAO/
WHO Expert Consultation. Rome, FAO, 
2010. 
 134 Koletzko B, Bhutta ZA, Cai W, Cruchet S, 
Guindi ME, Fuchs GJ, Goddard EA, van 
Goudoever JB, Quak SH, Kulkarni B, 
Makrides M, Ribeiro H, Walker A: Compo-
sitional requirements of follow-up formula 
for use in infancy: recommendations of an 
international expert group coordinated by 
the Early Nutrition Academy. Ann Nutr 
Metab 2013; 62: 44–54. 
 135 Koletzko B, Sauerwald T, Demmelmair H, 
Herzog M, von Schenck U, Bohles H, Wen-
del U, Seidel J: Dietary long-chain polyun-
saturated fatty acid supplementation in in-
fants with phenylketonuria: a randomized 
controlled trial. J Inherit Metab Dis 2007; 30: 
 326–332. 
 136 ESPGHAN Committee on Nutrition; Agos-
toni C, Buonocore G, Carnielli VP, De Cur-
tis M, Darmaun D, Decsi T, Domellof M, 
Embleton ND, Fusch C, Genzel-Borovicze-
ny O, Goulet O, Kalhan SC, Kolacek S, Ko-
letzko B, Lapillonne A, Mihatsch W, More-
no L, Neu J, Poindexter B, Puntis J, Putet G, 
Rigo J, Riskin A, Salle B, Sauer P, Shamir R, 
Szajewska H, Thureen P, Turck D, van Gou-
doever JB, Ziegler EE: Enteral nutrient sup-
ply for preterm infants: commentary from 
the European Society of Paediatric Gastro-
enterology, Hepatology and Nutrition Com-
mittee on Nutrition. J Pediatr Gastroenterol 
Nutr 2010; 50: 85–91. 
 137 Makrides M, Gibson RA, McPhee AJ, Col-
lins CT, Davis PG, Doyle LW, Simmer K, 
Colditz PB, Morris S, Smithers LG, Willson 
K, Ryan P: Neurodevelopmental outcomes 
of preterm infants fed high-dose docosa-
hexaenoic acid: a randomized controlled tri-
al. JAMA 2009; 301: 175–182. 
 138 Koletzko B, Poindexter B, Uauy R: Recom-
mended nutrient intake levels for stable, ful-
ly enterally fed very low birthweight infants; 
in Koletzko B, Poindexter B, Uauy R (eds): 
Nutritional Care of Preterm Infants. Basel, 
Karger, 2014, pp 300–305. 
 139 Ministry of Health, Labour, and Welfare, 
Japanese Government: The National Health 
and Nutrition Survey Japan 2011. Tokyo, 
Ministry of Health, Labour and Welfare, 
Japanese Government, 2012. 
 140 Kim CS, Ko SH, Kwon HS, Kim NH, Kim 
JH, Lim S, Choi SH, Song KH, Won JC, Kim 
DJ, Cha BY; Taskforce Team of Diabetes 
Fact Sheet of the Korean Diabetes Associa-
tion: Prevalence, awareness, and manage-
ment of obesity in Korea: data from the 
 Korea National Health and Nutrition Exam-
ination Survey (1998–2011). Diabetes Metab 
J 2014; 38: 35–43. 
 141 Bae SG, Kim JY, Kim KY, Park SW, Bae J, 
Lee WK: Changes in dietary behavior among 
adolescents and their association with gov-
ernment nutrition policies in Korea, 2005–
2009. J Prev Med Public Health 2012; 45: 47–
59. 
 142 Nguyen VQ, Goto A, Nguyen TV, Vo KT, Ta 
TM, Nguyen TN, Nguyen TM, Ho MB, Phan 
NA, Vu HH, Truong TM, Nguyen HT: Prev-
alence and correlates of zinc deficiency in 
pregnant Vietnamese women in Ho Chi 
Minh City. Asia Pac J Clin Nutr 2013; 22: 
 614–619. 
 143 Chiang JK, Lin YL, Chen CL, Ouyang CM, 
Wu YT, Chi YC, Huang KC, Yang WS: Re-
duced risk for metabolic syndrome and in-
sulin resistance associated with ovo-lacto-
vegetarian behavior in female Buddhists: a 
case-control study. PLoS One 2013; 
 8:e71799. 
 144 Cui X, Dai Q, Tseng M, Shu XO, Gao YT, 
Zheng W: Dietary patterns and breast cancer 
risk in the Shanghai Breast Cancer Study. 
Cancer Epidemiol Biomarkers Prev 2007; 16: 
 1443–1448. 
 Koletzko   et al. Ann Nutr Metab 2014;65:49–80
DOI: 10.1159/000365767
80
 145 Setiarini A, Utari DM, Mardatilah M, Putra 
WKY, Sudiarti T: Development of food pyr-
amid for vegetarian in Indonesia. Vegetari-
an Nutr J 2013; 1: 8–13. 
 146 Huffman SL, Harika RK, Eilander A, Osend-
arp SJ: Essential fats: how do they affect 
growth and development of infants and 
young children in developing countries? A 
literature review. Matern Child Nutr 2011; 
 7(suppl 3):44–65. 
 147 Yakes EA, Arsenault JE, Islam MM, Ahmed 
T, German JB, Drake C, Hossain MB, Lew-
is BL, Rahman AS, Jamil KM, Brown KH: 
Dietary intake of polyunsaturated fatty ac-
ids among breast-feeding and non-breast-
feeding 24- to 48-month-old children in 
Bangladesh. J Pediatr Gastroenterol Nutr 
2011; 52: 351–359. 
 148 Glew RH, Huang YS, Vander Jagt TA, Ch-
uang LT, Bhatt SK, Magnussen MA, Vander 
Jagt DJ: Fatty acid composition of the milk 
lipids of Nepalese women: correlation be-
tween fatty acid composition of serum phos-
pholipids and melting point. Prostaglandins 
Leukot Essent Fatty Acids 2001; 65: 147–156. 
 149 Brenna JT, Varamini B, Jensen RG, Diersen-
Schade DA, Boettcher JA, Arterburn LM: 
Docosahexaenoic and arachidonic acid con-
centrations in human breast milk world-
wide. Am J Clin Nutr 2007; 85: 1457–1464. 
 150 Peng Y, Zhou T, Wang Q, Liu P, Zhang T, 
Zetterstrom R, Strandvik B: Fatty acid com-
position of diet, cord blood and breast milk 
in Chinese mothers with different dietary 
habits. Prostaglandins Leukot Essent Fatty 
Acids 2009; 81: 325–330. 
 151 Yuhas R, Pramuk K, Lien EL: Human milk 
fatty acid composition from nine countries 
varies most in DHA. Lipids 2006; 41: 851–858. 
 152 Barbarich BN, Willows ND, Wang L, Clan-
dinin MT: Polyunsaturated fatty acids and 
anthropometric indices of children in rural 
China. Eur J Clin Nutr 2006; 60: 1100–1107. 
 153 Smit EN, Oelen EA, Seerat E, Muskiet FA, 
Boersma ER: Breast milk docosahexaenoic 
acid (DHA) correlates with DHA status of 
malnourished infants. Arch Dis Child 2000; 
 82: 493–494. 
 154 Agostoni C, Giovannini M, Sala D, Usuelli 
M, Livio L, Francescato G, Braga M, Riva E, 
Martiello A, Colombo C, Marangoni F, Gal-
li C: Double-blind, placebo-controlled trial 
comparing effects of supplementation of 
two micronutrient sprinkles on fatty acid 
status in Cambodian infants. J Pediatr Gas-
troenterol Nutr 2007; 44: 136–142. 
155 Stein AD, Wang M, Martorell R, Neufeld 
LM, Flores-Ayala R, Rivera JA, Ramakrish-
nan U: Growth to age 18 months following 
prenatal supplementation with docosa-
hexaenoic acid differs by maternal gravidity 
in Mexico. J Nutr 2011;141:316–320. Doi: 
10.3945/jn.110.128215. Epub 2010 Dec 22.
156 Miles EA, Noakes PS, Kremmyda LS, Vlacha-
va M, Diaper ND, Rosenlund G, Urwin H, 
Yaqoob P, Rossary A, Farges MC, Vasson 
MP, Liaset B, Frøyland L, Helmersson J, Basu 
S, Garcia E, Olza J, Mesa MD, Aguilera CM, 
Gil A, Robinson SM, Inskip HM, Godfrey 
KM, Calder PC: The Salmon in Pregnancy 
Study: study design, subject characteristics, 
maternal fish and marine n-3 fatty acid in-
take, and marine n-3 fatty acid status in ma-
ternal and umbilical cord blood. Am J Clin 
Nutr 2011;94(6 suppl):1986S–1992S. Doi: 
10.3945/ajcn.110.001636. Epub 2011 Aug 17.
157 de Jong C, Kikkert HK, Fidler V, Hadders-
Algra M: The Groningen LCPUFA study: no 
effect of postnatal long-chain polyunsatu-
rated fatty acids in healthy term infants on 
neurological condition at 9 years. Br J Nutr 
2010;104:566–572. Doi: 10.1017/S00071145 
10000863. Epub 2010 Apr 7. PubMed PMID: 
20370943.
158 Westerberg AC, Schei R, Henriksen C, 
Smith L, Veierod MB, Drevon CA, et al: At-
tention among very low birth weight infants 
following early supplementation with doco-
sahexaenoic and arachidonic acid. Acta Pae-
diatr 2011;100:47–52. PubMed PMID: 
WOS:000285101100014. English.
159 Drover J, Hoffman DR, Castañeda YS, Mo-
rale SE, Birch EE: Three randomized con-
trolled trials of early long-chain polyunsatu-
rated Fatty Acid supplementation on means-
end problem solving in 9-month-olds. Child 
Dev 2009;80:1376–1384. Doi: 10.1111/j. 
1467-8624.2009.01339.x.
160 Schwartz J, Dube K, Sichert-Hellert W, Kan-
nenberg F, Kunz C, Kalhoff H, Kersting M: 
Modification of dietary polyunsaturated fat-
ty acids via complementary food enhances 
n-3 long-chain polyunsaturated fatty acid 
synthesis in healthy infants: a double blind-
ed randomised controlled trial. Arch Dis 
Child 2009;94:876–882. Doi: 10.1136/adc. 
2008.146027. Epub 2009 Feb 4.
